[COMPANY_001] / Incyte Corp. Confidential Page 2
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
Table of contents
Table of contents ................................................................................................................. [ADDRESS_879247] of abbreviations ............................................................................................................ 8
Glossary  of terms ............................................................................................................... 11
Amendment 4 .................................................................................................................... 12
Amendment 3 .................................................................................................................... 15
1Background ........................................................................................................................ 24
1.1 Overview of my elofibrosis and current treatment options .................................... 24
1.2 Overview of INC424 (ruxolitinib) ......................................................................... 25
1.2.1 Preclinical studies .................................................................................. 26
1.2.2 Clinical pharmacology  of INC424 ........................................................ 26
1.2.3 INC424 clinical safety  in healthy  volunteers ........................................ 27
1.2.4 INC424 clinical safety  and efficacy  in m yelofibrosis patients 
(Phase I/II stud y)................................................................................... 27
1.3 Study  purpose/rationale ......................................................................................... [ADDRESS_879248] ives..................................................................................................... 33
2.2 Study  endpoints ..................................................................................................... 33
3Investigational plan ................................ ................................ ................................ ........... 36
3.1 Study  design ........................................................................................................... 36
3.1.1 Investigational treatment, other study  treatment, study  treatment, 
supportive treatment .............................................................................. 39
3.1.2 Treatment arms ...................................................................................... 39
3.1.3 Treatment duration ................................................................................ 39
3.1.4 Patient numbering and sc reening .......................................................... 39
3.1.5 Treatment assignment/randomization ................................................... 40
3.1.6 Treatment blinding ................................................................................ 40
3.2 Rationale for the stud y design ............................................................................... 40
3.3 Purpose and timing of interim anal yses/design adaptations .................................. 40
3.4 Rationale for the dose/regimen selection and treatment duration ......................... 41
3.4.1 Clinical safet y and tolerability .............................................................. 41
3.4.2 Clinical pharmacod ynam ics.................................................................. 42
3.4.3
Clinical pharmacokinetics..................................................................... 42
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879249]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879250]

[COMPANY_001] / Incyte Corp. Confidential Page 3
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
3.4.4 Non-clinical data ................................ ................................ ................... 44
3.4.5 Dose selection ....................................................................................... 45
3.5
Rationale for choice of combination drugs............................................................ 46
3.6 Rationale for choice of comparators dru gs............................................................ 46
3.7 Sub-studies ............................................................................................................. 46
3.8 Definition of end of the study ................................................................................ 46
3.9 Early study termination .......................................................................................... 47
4Population .......................................................................................................................... 47
4.1 Inclusion criteria .................................................................................................... 48
4.2 Exclusion criteria ................................................................................................... 49
5Treatment ........................................................................................................................... 50
5.1 Treating the patient ................................................................................................ 50
5.1.1 Administration ....................................................................................... 50
5.1.2 Dosing and treatment schedule ............................................................. 51
5.1.3 Dose modification and dose delay ........................................................ 56
5.1.4 Treatment interruption and treatment discontinuation .......................... 57
5.1.5 Dose reduction of INC424 for concomitant CYP inhibitor usage ........ 63
5.1.6 Optional dose tapering strategy  for INC424 in the event of 
disco
ntinuation ...................................................................................... 64
5.1.7
Rescue medication ................................................................................ 64
5.1.8 Permitted concomitant therap y
............................................................. 64
5.1.9 Permitted concomitant therap y requiring caution and/or action ........... 64
5.1.10 Prohibited concomitant therap y
............................................................ 65
5.1.11
Hormonal contraception allowed/excluded........................................... 65
5.2 Study  drug(s) ................................ ................................ ................................ ......... 66
5.2.1 Packaging and labeling ......................................................................... 66
5.2.2 Supply , receipt and storage ................................................................... 66
5.2.3 Dispensing and preparation ................................................................... 66
5.2.4 Drug compliance and accountability ..................................................... 66
5.2.5 Disposal and destruction ....................................................................... 67
6
Visit schedule and assessments ......................................................................................... 67
6.1 Study  flow and visit s chedule ................................................................................ 67
6.1.1
Screening examination.......................................................................... 74
6.1.2 Run-in period ........................................................................................ 75
6.1.3 Treatment period ................................................................................... 75
6.1.4 Discontinuation of Study Treatment/ Study .......................................... 76
6.1.5 Follow up for safet y evaluations ........................................................... 78
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879251]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879252]

[COMPANY_001] / Incyte Corp. Confidential Page 4
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
6.1.[ADDRESS_879253] abnormalities ................................................................ 87
7.2 Serious adverse events ........................................................................................... 87
7.2.1
Definitions............................................................................................. 87
7.2.2
Reporting............................................................................................... 88
7.2.3 Emergency  unblinding of treatment assignment ................................... 88
7.3 Pregnancies ............................................................................................................ 88
7.4 Warnings and precautions ...................................................................................... 89
7.5 Data Monitoring Committee .................................................................................. 89
7.6 Steering Committee ............................................................................................... 89
8Data review and management ........................................................................................... 89
8.1 Data confidentiality ............................................................................................... 89
8.2 Site monitoring ...................................................................................................... 90
8.3
Data collection....................................................................................................... 90
8.4 Database management and quality  control ................................ ............................ 90
9Statistical methods and data anal ysis................................................................................ 91
9.1 Analy sis sets .......................................................................................................... 92
9.1.1 Full Anal ysis Set ................................................................................... 92
9.1.2 Safet y Set .............................................................................................. 92
9.1.3 Dose -determining Set ............................................................................ 92
9.1.4 Pharmacokinetic anal ysis set
................................................................. 92
9.2 Patient demographics/other baseline characteristics ............................................. 93
9.3 Treatments (stud y drug, concomitant therapi[INVESTIGATOR_014], compliance) ............................... 93
9.4 Primary  objective ................................................................................................... 93
9.4.1 Variable ................................................................................................. 93
9.4.2 Statistical hy pothesis, 
model, and method of analy sis.......................... 94
9.4.3 Handling of missing values/censoring/discontinuations ....................... 98
9.4.4 Supportive anal yses............................................................................... 99
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879254]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879255]

[COMPANY_001] / Incyte Corp. Confidential Page 5
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
9.5 Secondary  objectives ................................ ................................ ............................. 99
9.5.1 Efficacy  objectives ................................................................................ 99
9.5.2 Safet y objectives ................................................................................... 99
9.5.3 Resource utilization ............................................................................. 101
9.5.5
Pharmacokinetics, pharmacod ynamics and pharmacokinetics -
pharmacod ynamics .............................................................................. 101
9.6 Exploratory  objectives ......................................................................................... 102
9.7 Interim anal ysis.................................................................................................... 103
9.8
Sample size calculation........................................................................................ 103
10Ethical considerations and administrative procedures .................................................... 104
10.1 Regulatory
 and ethical compliance ...................................................................... 104
10.2 Responsibilities of the I nvestigator and IRB/IEC/REB ....................................... [ADDRESS_879256] keepi[INVESTIGATOR_5304] ..................... 105
10.7 Confidentiality  of study  documents and patient records ..................................... 106
10.8 Audits and 
inspections......................................................................................... 106
10.9 Financial disclosures ............................................................................................ 106
11Protocol adherence .......................................................................................................... 106
11.1 Amendments to the protocol ................................................................................ 106
12
References (available upon request)................................ ................................ ................ 107
13Appendices ...................................................................................................................... 109
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879257]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879258]

[COMPANY_001] / Incyte Corp. Confidential Page 6
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
List of A ppendices
1.Classification and diagnosis of my eloproliferative neoplasms and proposed criteria for the 
diagnosis of post -polycythemia vera and post- essential thrombocy themia my elofibrosis
3.Information Regarding Effectiveness of Contraceptive Methods
4.Drugs that interfere with coagulation or in hibit platelet function
5.Hepatic encephalopath y grading according to West Haven Criteria
6.MDRD -eGFR Formula
7.CYP3A4 I nhibitors and Inducers
8. [LOCATION_001] Heart Association (NYHA) Functional Classification
11.Eastern Cooperative Oncology  Group (ECOG) Performance Status
12.Clinical L aboratory  Tests
13.Prior calibration, h ypothetical dose escalation scenarios, and operating characteristics of 
the Bay esian logistic regression model
List of figur es
Figure 1 -1 Kaplan -Meier anal ysis of time to 1stnew or worsening grade 3 or 4 
thrombocy topenia in INCB [ZIP_CODE]- 251 study ....................................... 29
Figure 1 -
2 Median percent change from baseline in platelets by  [CONTACT_655151] 184 24-251 study ................................ .......... 30
Figure 3 -1 Study  design .......................................................................................... 38
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879259]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879260]

[COMPANY_001] / Incyte Corp. Confidential Page 7
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
List of tables
Table 1-1 Median survival of MF patients according to risk category ................. 24
Table 1-2 Incidence of thrombocy topenia in the study  INCB [ZIP_CODE]-251 ............ 31
Table 2-1 Objectives and related endpoints .......................................................... 35
Table 3
-1 Study  drugs ............................................................................................ 39
Table 5
-1 Treatment and treatment schedule ........................................................ 50
Table 5
-2 Dose levels ............................................................................................ 51
Table 5
-3 Criteria for defining dose- limiting toxicities ......................................... 55
Table 5
-4 Criteria for interruption and re- initiation of INC424 treatment –
Recommended dose modifications ................................ ....................... [ADDRESS_879261] amendment 4 - Core study  period 
(from screening to Day  168) ................................................................. [ADDRESS_879262] amendment 4 –Extension 
study  period ........................................................................................... 73
Table 6
-4 Sample collection time windows for population pharmacokinetic 
assessments ........................................................................................... 83
Table 9
-1 Final prior for the current study ............................................................ 95
Table 9
-2 Posterior estimates for BLRM based on stud y [INCB [ZIP_CODE]-251] ...... 96
Table 9-3 Predicted probabilit y of DLT quantiles for stratum 1 an d 
distribution of log(alpha), log(beta) after accounting for between 
trial heterogeneity .................................................................................. 97
Table 9
-4 Distributions of model parameters and final prior distribution ............. 97
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879263]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879264]

[COMPANY_001] / Incyte Corp. Confidential Page 8
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
List of abbreviations
AE Adverse Event
ALT Alanine A minotransferase/ Glutamic Pyruvic Transaminase/GPT
ANC Absolute Neutrophyl Count
AST Aspartate Aminotransferase/G lutami c Oxaloacetic Transaminase/GOT
AUC Area U nder Curve
b.i.d. bis in diem /twice a day
BUN Blood Urea Nitrogen
CDP Clinical Development Plan
CTH Clinical Trial H ead
BLRM Bayesian Logistic Regression Model
BMI Body Mass Index
CBC Complete Blood Count
CML Chronic Myelogenous Leukemia
CRF Case R eport/ Record Form
eCRF Electronic Case Report/ Record Form
CRO Contract Research Organization
CSR Clinical Study Report
CSR addendum An addendum to Clinical Study Report (CSR) that captures all the additional information that 
is not included in the CSR
CTCAE Common Terminology Criteria for Adverse Events
CTT Clinical Trial Team
CYP Cytochrome
DDS Dose -Determining Set
DLT Dose L imiting Toxicity
EC Ethics Committee
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
EDC Electronic Data Capture
EOT End O f Treatment
EPO Erythropoietin
ET Essential Thrombocythemia
EWOC Escalation With Overdose Control
FDP Fibrinogen Degradation Products
FPFV First Patient First Visit
GCSF Granulocyte Colony Stimulating F actor
GI Gastrointestinal
hCG human Chorionic Gonadotropin
IB Investigator Brochure
ICF Informed Consent Form
i.v. Intravenous(ly)
ICH International Conference on Harmonization
IEC Independent Ethics Committee
IMS Integrated Medical Safety
IN Investigator Notification
INR International Normalized ratio
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879265]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879266]

[COMPANY_001] / Incyte Corp. Confidential Page 9
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System and 
Interactive W eb Response System
IWG International Working Gro up,
LPLV Last Patient Last Visit
LPFV Last Patient First Visit
MAP Master Analysis Plan documents project standards in the statistical methods which will be 
used within the individual clinical trial RAP documentation.
MDRD -eGFR Modification of Diet in Renal Disease estimated Glomerular F iltration Rate
MedDRA Medical Dictionary for Regulatory Activities
MF Myelofibrosis
MPN Myeloproliferative Neoplasm
MTD Maximum Tolerated D ose
MSSD Maximum Safe Starting Dose
NSAIDs Non-Steroidal Anti-Inflammatory Drugs
NYHA [LOCATION_001] Heart Association
NONMEM Non-linear Mixed Effects Modeling
o.d. omnia die /once a day
PAS Pharmacokinetic Analysis Set
PD Pharmacodynamic
PET-MF Post Essential Thrombocythemia Myelofibrosis
PHI Protected Health Information
PK Pharmacokinetic
PLT Platelet
PMF Primary Myelofibrosis
p.o. per os /by [CONTACT_1966]/orally
PPV- MF Post Polycythemia V era M yelofibrosis
PTT Partial Thromboplastin time
PV Polycythemia Vera
q.AM Every morning
q.PM Every afternoon
RAP The Report and Analysis Plan (RAP) is a regulatory document which provides evidence of 
preplanned analyses
REB Research Ethics Board
SAE Serious Adverse Event
SOP Standard Operating Procedure
SSF Screening Symptom Form
STAT3 Signal transducer and activator of transcription [ADDRESS_879267] Upper Limit of Normal
WBC White Blood Cell
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879268]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879269]

[COMPANY_001] / Incyte Corp. Confidential Page 10
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
WHO World Health Organization
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879270]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879271]

[COMPANY_001] / Incyte Corp. Confidential Page 11
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_79582] (eg: q28 days)
Enrollment Point/time of patient entry into the study; the point at which informed consent 
must be obtained (i.e. prior to starting any of the procedures described in the 
protocol)
Investigational drug The study drug whose properties are being tested in the study; t his definition is 
consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug.”
Investigational treatment Drug swhose properties are being testing in the study as well as their 
associated placebo and active treatment controls (when applicable). This also 
includes approved drugs used outside of their indication/approved dosage, or 
that are tested in a fixed combination. Investigational treatment generally does 
not include other study treatments administered as concomitant backgr ound 
therapy required or allowed by [CONTACT_213734]/dosage
Medication number A unique identifier on the label of each study drug package in studies that 
dispense study drug using an Interactive Response Technology
Other study treatment Any drug administered to the patient as part of the required study procedures 
that was not included in the investigational treatment
Patient number A number assigned to each patient who enrolls in the study. W hen combined 
with the investigative site number, a unique identifier is created for each 
patient in the study
Period A subdivision of the study timeline; divides stages into smaller functional 
segments such as screening, titration, etc.
Patient withdrawal Point/time when the patient exits from the study; at this time all study drug 
administration is discontinued and no further assessments are planned, unless 
the patient will be followed for progression and/or survival
Randomization number A unique identifier assigned to each randomized patient, corresponding to a 
specific treatment arm assignment
Stage related to study time line A major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc .
Stage in cancer The extent of a cancer in the body. Staging is usually based on the size of the 
tumor, whether lymph nodes contain cancer, and whether the cancer has 
spread from the original site to other parts of the body
Stop study participation Point/time at which the patient c ome in for a final evaluation visit or when 
study drug isdiscontinued whichever is later
Study drug Any drug administered to the patient as part of the required study procedures; 
includes investigational drug and any comb ination or control drug(s)
Study treatment Includes any drug or combination of drugs in any study arm administered to 
the patient (subject) as part of the required study procedures, including 
placebo and active drug run -ins.
In specific examples where it is important to judge study treatment relationship 
relative to a drug component of a combination treatment, study treatment in 
this case can refer to a drug component
Study drug discontinuation Point/time when patient permanently stops taking study drug f or any reason; 
may or may not also be the point/time of patient withdrawal
Variable Identifier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified timepoints
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879272]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879273]

[COMPANY_001] / Incyte Corp. Confidential Page 12
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
Amendment [ADDRESS_879274] been screened.  Of the 58 patients screened, 46 patients started study  treatment 
and 12 patients were declared as screen failures.  The study  consisted of a dose escalation 
phase and a safet y expansion phase, and 2 different Stratums to which patients were assigned 
based on their platelet counts at baseline. In Stratum 1 (for baseline PLT counts of < 100 x 
109/L  and ≥ 75 x 109/L), 24 patients were enrolled into the dose escalation phase and 3 
patients were enrolled into the safet y expansion phase for a total of 27 patients. Of the 27 
patients in Stratum 1, 9 patients in the dose escalation phase and 3 patients in the safety 
expansion phase were e valuated at the maximum safe starting dose (MSSD) of 15 mg BID. In 
Stratum 2 (for baseline PLT counts of < 75 x 109/L  and ≥ 50 x 109/L), [ADDRESS_879275] cycle (28 days) of treatment. However, 
observations from the planned interim analy sis indicated that patients who started treatment at 
the [ADDRESS_879276] 
cycle of treatment. A majority  of the patients who had dose reductions eventually  continued 
study  treatment at the 10 mg BID dose or lower. Additionally , a relevant clinical benefit was 
observed across all starting dose levels, including those who started treatment at the 10 mg 
BID dose levels. These observations warrant further exploration of the 10 mg BID dose level 
as the starting dose in Stratum 1 for myelofibrosis patients with platelet counts of < 75 x 
109/L  and ≥ 50 x 109/ L.
Therefore, the purpose of this amendment is to revise the starting dose to 10 mg BID, from 
the current starting dose of 15 mg BID, and is applicable for all new patients entering the 
safet y expansion phase of Stratum 1.
Following the approval of Amendme nt 4, new patients enrolled to Stratum 1’s safet y 
expansion phase will begin treatment with ruxolitinib at [ADDRESS_879277] Patient’s First Visit (LPFV) will occur 
on [ADDRESS_879278].  Patients already  taking the 15 mg BID dose in 
Stratum 1’s safet y expansion phase will continue to take their assigned dose.  
Stratum 2 will remain unchanged 
and maintain its original enrollment requirement of 10 
patients at the MSSD.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879279]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879280]

[COMPANY_001] / Incyte Corp. Confidential Page 16
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
Changes to the protocol
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underlined for insertions.
The following sections have been changed:
Section 3.1 Study  design
Section 3.1.3 Treatment duration
Section 3.3 Purpose and timing of interim anal yses/design adaptations
Section 3.8 Definition of End of the study
Section 5.1.4 Treatment interruption and treatment discontinuation and Table 5 -4Criteria 
for interruption and re -initiation of I NC424 treatment – Recommended dose modifications
Section 6.1 Study  flow and visit sche dule: Table 6- 1 : Visit Evaluation Schedule and 
Table 6- 2: Laboratory  Assessment Schedule
Section 6.1.3 Treatment period
Section 6.1.4. End of treatment and withdrawal visit
Section [IP_ADDRESS] Cardiac assessments
Section [IP_ADDRESS] Pharmacokinetic blood sample c ollection and handling

Section 9: Statistical methods and data anal ysis

Section 9.7 I nterim anal ysis
IRB/IEC/REB A pproval
A copy of this amended protocol will be sent to the Instit utional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879281]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879282]

[COMPANY_001] / Incyte Corp. Confidential Page 17
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
Amendment 2 for the [LOCATION_008] only
Amendment rationale
The MHRA has requested a change to the major rationale of Amendment 1 to remove the 
wording ‘until ruxolitinib is commercially  available’ as this is not an acceptable treatment 
end-point. A specified length of treatment is an acceptable end-point and this has been 
provided.
The rationale for the length of study treatment for Amendment 1 is as follows:
To extend the treatment period for patients benefiting from the study  drug after the Study  
Day 168 visit.
If based on investigator’s judgment patients are benefiting from treatment, these patients 
will b e able to continue on the study  until [ADDRESS_879283] access to 
study  drug through commercial supplies [if applicable b y local regulations], whichever 
comes first.
The 30 June 2013 date may  be re -evaluated in case the drug is not co mmercially  available 
at that time, and an amendment will be issued to extend the treatment duration.
The above rationale for the length of study treatment for Amendment 2 will read as 
follows for the [LOCATION_008] only:
To extend the treatment period for ongoing patients benefiting from the study  drug after 
the Study  Day  168 visit.
All patients will be treated until L PFV plus 168 day s; the minimum treatment duration for 
any patient will therefore be 168 day s if the patient is not permanently  discontinued f or 
other reasons e.g. adverse event.
The treatment duration may be re -evaluated at that time, and an amendment issued to 
extend the treatment duration.
Study status
Fifteen patients have been screened for this study . Sixpatients were enrolled and nine patients 
were screen failures. Two of the enrolled patients have discontinued treatment.
Changes to the protocol
The following sections have been changed:
Section 3.1, Section 3.1.3, Section 3.8, Section 6.1.3, and Section 6.1.4: Treatment endpoint 
revised to LPFV plus [ADDRESS_879284] 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation. In addition, if the changes herein affect the Informed Consent, sites are 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879285]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879286]

[COMPANY_001] / Incyte Corp. Confidential Page 18
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended protocol.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879287]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879288]

[COMPANY_001] / Incyte Corp. Confidential Page 19
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
Amendment 1
Amendment rationale
The rationale for the amendment is as follows:
To extend the treatment period for patients benefiting from the stud y drug after the Stud y 
Day 168 visit.
If based on investigator’s judgment patients are benefiting from treatment, these 
patients will be able to continue on the study  until [ADDRESS_879289] access to study  drug through commercial supplies [if applicable by  [CONTACT_13125]], whichever comes first.
The 30 June 2013 date may  be re -evaluated in case the drug is not commercially  
available at that time, and an amendment will be issued to extend the tre atment 
duration.
To re -evaluate the inclusion & exclusion criteria to the study :
New safet y data from [CINC424A2352] and the [I NCB 1824 -351] trials provided 
further information on the safet y of treating patients with low platelet values with 
INC424. Therefore some inclusion & exclusion criteria are no longer necessary .
Fluctuation in the platelet count inherent to the nature of the disease has precluded 
potential patients’ qualification in the study . Therefore the qualify ing platelet criteria 
have been revised.
Inclusion & exclusion criteria were too strict, therefore hampering patients’ accrual.
Definition of disease progression will be amende d to be in line with the most current 
[CINC424A2352] trial version.
Other non major changes are included in this amendment.
Extend the patient treatment duration . The following items were reviewed:
Study  duration: amended to provide the drug to patients be nefiting from the study  drug 
until [ADDRESS_879290] access to study drug through commercial 
supplies [if applicable by [CONTACT_427]], whichever comes first. The 30 June 2013 date 
may be re -evaluated in case the drug is not comme rciall y available at that time , and an 
amendment will be issued to extend the treatment duration.
Conditions to continue in the extension period: all patients who are benefiting from study  
drug will have the option to continue the study  treatment unless at least one withdrawal 
criteria is met and onl y if the treatment with INC424 is considered the patient’s best 
therapeutic option b y the Investigator. Patients must have completed the Study Day  168 
visit.
Conditions for maximum intra
-patient dose escalation after the Study  Day  168 visit. Each 
patient may  be treated at the higher of:
the MSSD level established for that stratum or
[ADDRESS_879291] dose which has shown 
efficacy  in the completed Phase III [I NCB 182 4-351] study  and because the safet y profile 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879292]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879293]

[COMPANY_001] / Incyte Corp. Confidential Page 23
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
6.1.3 and [IP_ADDRESS]: Laboratory -only visits.
Table 5- 5: dose escalation guidelines following thrombocy topenia different than grad e 4 
events.
IRB/IEC
A copy of this amended protocol will be sent to the Institutional Review Boards 
(IRBs)/Independent Ethics Committees (I ECs) and Health Authorities.
The changes described in this amended protocol require IRB/IEC approval prior to 
impleme ntation. In addition, if the changes herein affect the Informed Consent, sites are 
required to update and submit for approval a revised Informed Consent that takes into account 
the changes described in this amended pr otocol.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879294]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879295]

[COMPANY_001] / Incyte Corp. Confidential Page 24
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
1 Background
1.1 Overview  of myelofib rosis and current treatment options
The four classic myeloproliferative neoplasms (MPNs) include chronic myelogenous 
leukemia (CML), polycythemia vera (PV), essential thrombocy themia (ET) and primary 
myelofibrosis (PMF). Myelofibrosis (MF) can present as ade novo disorder (PMF) or evolve 
secondaril y from previous PV or ET (post-PV-MF or post ET-MF). Regardless of whether 
MF is a primary  or secondary  disorder, it is characterized by a clonal stem cell proliferation 
associated with production of elevated serum levels of multiple inflammatory  and 
proangiogenic cytokines, a characteristic bone marrow stromal pattern that includes varying 
degrees of collagen fibrosis, osteosclerosis and angiogenesis and a peripheral blood smear 
showing a leukoery throblastic pattern with varying degrees of circulating progenitor cells. 
Clinically , MF is characterized by [CONTACT_488256], leukopenia or leukocy tosis, 
thrombocytopenia or thrombocy themia and multi- organ extramedullary  hematopoiesis most 
prominently  involving the liver and spleen. Patients may experience severe constitutional 
symptoms, sequelae of massive splenomegal y (pain, limitations of movement, early satiet y 
and shortness of breath, hepatic obstruction, and splenic infarction), a hypermetabolic state 
with cachexi a, progressive hematopoietic failure, progression to leukemia, and premature 
death.
The median age at diagnosis is approximately  60 to 65 years. The incidence of PMF has been 
estimated at 1.5 cases per 100,000 people. Survival in MF varies with the presenc e or absence 
of specific risk factors. (Cervantes et al 2009) have recentl y published a multi -center analy sis 
of risk factors and their impact on prognosis in patients with MF. They  identified age of 
greater than 65 years, presence of constitutional sy mptoms (weight loss > 10% of the baseline 
value in the year preceding PMF diagnosis , unexplained fever, or excessive night sweats
persisting for more than 1 month ), anemia (Hgb less than 10g/dL), leukocy tosis (white blood 
cell count (WBC )greater than 25 x109/L), and a circulating blast percentage of 1% or higher 
as individually  predictive of outcome. They  demonstrated that patients could be distinctl y 
grouped into four categories without overlappi [INVESTIGATOR_655123] ( Table 1 -1).
Table 1
-1 Median survival of MF patients according to risk category
No of risk factors Risk category Median survival (months)
0 Low 135
1 Intermediate -1 95
2 Intermediate -2 48
3 or more High 27
For a subset of patients who are younger (generally  less than 65 years), otherwise healthy  and 
have a histocompatible donor, allogeneic stem cell transplantation may provide a curative 
option, although with substantial (10-20%) risks of mortality , (Deeg et al 2003). D rug 
therapi[INVESTIGATOR_99399], including hydroxyurea, busulfan, 6-mercaptopurine, anagrelide, thalidomide, 
lenalidomide, interferon, corticosteroids, and erythropoiesis stimulating agents or growth 
factors, have not been shown to improve survival. Some can increase the risk of leukemic 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879296]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879297]

[COMPANY_001] / Incyte Corp. Confidential Page 27
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
requiring dialy sis showed prolonged PD activity without a demonstrable effect on INC424 
clearance. In patients with mild, moderat e and severe hepatic impairment, the mean total 
AUCs of INC424 were 88%, 29% and 66% higher, respectivel y, compared to patients with 
normal hepatic function. Terminal half-life of INC424 was increased in patients with hepatic 
impairment by [CONTACT_3450]  2-fold compared to health y controls. The patients with severe 
hepatic impairment showed modestl y protracted PD activit y compared to the other hepaticall y 
impaired patients who display ed PD activity  similar to the healthy controls.
Additional details as to the clinical pharmacology of INC424 may  be found in the IB.
1.2.3 INC424 clinical safety in healthy  volunteers
INC424 has been administered in single or multiple doses to over 200 healthy  volunteers . In 
single dose studies, INC424 has a well established safet y profile and has been well tolerated 
with Adverse Events (AEs) generally  mild in intensity , reversible and of similar incidence 
following INC424 treatment compared with placebo or with other control treatments.
In a 10 -day multiple dose study , a total of 71 healthy  volunteers in 6 cohorts received doses of 
50 mg qd, 100 mg qd, 15 mg b.i.d. , 
25 mg b.i.d. or 50 mg b.i.d. INC424 or placebo ,
[INCB18424-132] study. INC424 was well tolerated in the study , with most AEs reported 
equally  by [CONTACT_655152]424 -treated and placebo -treated volunteers . Neutropenia was noted in [ADDRESS_879298] dose of INC424, 50 mg b.i.d. Neutropenia at the Grade 4 
level led to study  drug discontinuation on Day 5 in one volunteer and was reported as a 
Serious Adverse Event (SAE). There was a decline in mean absolute neutrophil count (ANC) 
and,to a lesser extent, in mean WBC count values with INC424 doses of [ADDRESS_879299] dose of study drug. Doses of 25 mg b.i.d. and 100 mg qd were determined to be the 
maximum tolerated doses (MTDs) in this study  based on the dose limiting toxicity  (DLT) of 
neutropenia.
A definitive QT stud y was carried out in 50 healthy volunteers, evaluating the e ffects of single 
doses of 25 mg or 200 mg INC424 compared with placebo and 400 mg moxifloxacin (positive 
control). The overall conclusion was that there appeared to be no adverse impact on ECG 
signaling (little change in heart rate, QRS duration, QTcF inte rval, and a slight, non -clinically 
significant, increase in PR interval) with the administration of INC424.
For additional details related to studies conducted in healthy  volunteers, consult the IB.
1.2.4 INC424 clinical safety and efficacy  in my elofibrosis pati
ents (Phase I/II 
study)
Study  [INCB [ZIP_CODE] -251] is an ongoing Phase I/IIopen label study  of INC424in patients with 
PMF, PPV-MF or PET-MFin patients with baseline platelet counts of at least 100 x 109/L. A 
totalof 154patients have been enrolled and treated at twice daily dose regimens of [ADDRESS_879300] had individually  titrated dose regimens that begin at doses of 10 mg 
b.i.d. , for patients with baseline platelets 100 x109/L -200 x109/L,or 15 mg b.i.d. , for patients 
with baseline platelets > 200 x109/L, with intra-patient dose escalation allowed up to doses of 
20 mg b.i.d. or 25 mg b.i.d. , respectivel y.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879301]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879302]

[COMPANY_001] / Incyte Corp. Confidential Page 31
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
For nearl y all patients, thrombocy topenia was rapi[INVESTIGATOR_655124] (Section 3.4.5 ); low platelet count was the primary  reason for study 
discontinuation for few patients.
Table 1-2 Incidence of t hrombocytopenia in the study  INCB [ZIP_CODE]- 251
Dose 10 mg 
b.i.d.15 mg 
b.i.d.25 mg 
b.i.d.50 mg 
b.i.d.25 mg 
qd50 mg 
qd100 mg 
qd200 mg 
qd
No of patients 30 35 47 5 6 22 6 3
Grade 3 6 (20%) 1 (2.9%) 12 (26%) 3 (60%) 1 (17%) 6 (27 %) 2 (33%) 0
Grade 4 0 0 5 (11 %) 1 (20%) 0 2 (9.1%) 0 1 (33%)
Total Gr 3 + 4 6 (20 %) 1 (2.9%) 17 (36%) 4 (80%) 1 (17%) 8 (36%) 2 (33%) 1 (33%)
The risk of spontaneous hemorrhage in any patient as a result of thrombocytopenia generall y 
does not become manifest until platelet counts fall below 10 to 20 x109/L (Slichter 2004). In 
[INCB [ZIP_CODE]
-251] study , the lowest platelet counts observed (grade 4 thrombocytopenia 
events) ranged from 6-22 x109/L. There was one patient with associated petechia e and no 
events of hemorrhage in the 9 patients with grade 4 platelet declines.
There were 2 deaths where the primary  cause of death was related to hemorrhage (upper 
gastric and cerebral hemorrhage). In the case of upper gastric hemorrha ge,the patient had 
emergency  surgical repair of a bleeding duodenal ulcer and died of post-operative 
complications. The PLT count was 447 x109/L and there was a history  of antecedent aspi[INVESTIGATOR_655125]. The event was considered unrelated to INC424 . In the case of cerebral 
hemorrhage , the patient had normal PLT count (201 x109/L), normal coagulation tests, and a 
history  of hypertension. T he event was assessed as possibly  related to INC424.
Other SAEs on study  [INCB [ZIP_CODE]-251] that involved hemorrhage of any kind have been 
examined. One patient was admitted to the hospi[INVESTIGATOR_4791] a PLTcount of 65x109/Land 
ultimately  required splenectomy , following which a post-
operative hemorrhage was noted in 
the surgical drains. The patient was discharged from the hospi[INVESTIGATOR_655126]. Another patient had 2 epi[INVESTIGATOR_655127]424. No information about PLT counts 
during the course of the 
event is provided. A patient suffered from gastrointestinal hemorrhage of unknown source 
with a PLT count of 510 x109/L. One patient had hematuria due to prostatic surgery ; the PLT 
count was 1,636 x109/L. Another patient suffering from splenomegal y developed an intra-
abdominal hematoma adjacent to the spleen, with a PLT count of 99 x109/L.One patient was 
hospi[INVESTIGATOR_655128] a PL T count of 93 x109/L.
Because of the advanced disease present in many  of the participants in study 
[INCB [ZIP_CODE]-251] , there are a number of SAEs that have been reported that were assessed as 
unrelated to study  drug. Of related SAEs reported in the study  to date, the most frequent are 
those reflecting inhibition of bone marrow function(s) (i.e. thrombocy topenia) and activation 
of inflammatory  cytokines when the inhibitory  influence of INC424 is removed due to drug 
interruption or discontinuation. See the IB for complete details on INC424 clinical study 
findings .
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879303]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879304]

[COMPANY_001] / Incyte Corp. Confidential Page 37
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
grade ≥ 3 febrile neutropenia*
grade ≥ [ADDRESS_879305] bilirubin ≥ 0.5 mg/dL
grade 3 non- hematologic toxicity  for ≥ 7 consecutive day s
grade 4 non- hematologi c toxicity
* At the discretion of the Investigator, laboratory values can be confirmed with a second 
assessment .In this case, only the result of the second assessment will be considered valid 
and final.
Adverse event s occurring after Study  Day28will not be considered DLTs , however, they 
may be considered in further decisions regarding the number of patients to enroll in a given 
dosing cohort. If a patient is not followed for the 28-day period following Study  Day 1 due to 
discontinuation ,for reasons other than DLTs, or if, from Study  Day 1 through Study  Day 28,
a patient misses > 6 consecutive doses of treatment or > 20% of the planned study  drug doses ,
another patient will be enrolled into that dose level and stratum. For toxicities which, by 
[CONTACT_108], require a time-window for them to be defined as DLTs (grade 3 non -hematologic 
toxicity  for ≥ 7 
consecutive days)a subsequent visit(s)and/or laboratory  assessment (s)must
be scheduled accordingly , in order for thistoxicity  to qualify  as a DLT. A minimum of 9 
evaluable patients from each stratum (stratum 1 consists of patients with baseline PLT counts 
75-99 x109/L and stratum 2 consists of patients with baseline PLT counts 50-74 x109/L)must 
be treated at the dose declared to be the MSSD .
Enrollment of patients and dose escalation will be performed as described in Section 
[IP_ADDRESS], 
Section [IP_ADDRESS], Section [IP_ADDRESS] and Section [IP_ADDRESS].
Intra -patient escalation during the dose escalation phase of the study will be allowed 
accordi ng to the rules described in the Section [IP_ADDRESS]
.
Following determination of the MSSD , a safet yexpansion phase will be conducted. Patients 
from both strata canbe enrolled simultaneousl y during the safet y expansion phase , allocated 
to a dose equal to the respective MSSD for their stratum .If the MSSD is the same in both 
strata, all patients in the safet y expansion phase will be treated with the same dose, regardless 
of the baseline PLT counts.
In thesafety expansion phase ,the safet yand tolerability of theMSSD will be further 
evaluated with the purpose of establishing that this dose is suitable for use in the low-platelet 
population of patients with MF. The Bayesian logistic regression model (BLRM) with 
escalation with overdose control (EWOC) will continue to be updated with data from patients 
participating in the safety expansion phase.
With the approval of Amendment 4, all new patients enrolled to Stratum 1’s safet y expansion 
phase will be given the [ADDRESS_879306] Patient’s 
First Visit (L PFV) will occur on [ADDRESS_879307].  
Patients alread y taking the 15 mg BID dose in Stratum 1’s safet y expansion phase will 
continue to take their assigned dose.  Stratum 2 will maintain its original enrollment 
requirement of 10 patients at the MSSD.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879308]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879309]

[COMPANY_001] / Incyte Corp. Confidential Page 39
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
3.1.1 Investigational treatment, other study  treatment, study  treatment, 
supportive treatment
During the study  all patients will receive INC424 tablets (see Section 5.1.1 ). INC424 tablets 
will be the only  investigational drug in this study (Table 3-1)
.
Table 3-1 Study  drugs
Study drugs
Investigational drug INC424 tablets (5 mg)
3.1.[ADDRESS_879310] of 2 periods: the initial 24 weeks core treatment period from Study  Day  
1 to Study  Day  168 and the extension treatment period from Study  Day  168 ( Week 24) until 3 
years (Week 156). The core study  period consists of a dose escalation phase and a safet y 
expansion phase (Figure 3 -
1).
[For patients in the [LOCATION_008] onl y:
After [ADDRESS_879311] access to study  drugoutside of this clinical trial, the patient 
may continue 
on study treatment until LPFV plus 3 years. After LPFV plus 3 years, if the 
study  treatment is not comme rciall y available and reimbursable in the [LOCATION_006], an alternative [LOCATION_006]-
specific free of charge (FOC) program exists to provide continued access for patients 
benefitting from the study  treatment]
3.1.4 Patient numbering and screening
Each patient is identified in the study by a patient ID number with a maximum length of 9 
digits, which is a combination of his/her site ID (the first 4 digits (maximum) of the patient 
ID) and patient number (the last 5 digits (maximum) of the patient ID) when the patient is first 
enrolled. The site IDis assigned by [CONTACT_655153]. ([COMPANY_001] 
Pharmaceuticals and Incyte Corporation are co-sponsors in this study . [COMPANY_001] is the Sponsor 
for the European sites only and Incyte is the Sponsor for the US sites only).Upon signing the 
informed consent form (ICF) , the patient number is assigned by [CONTACT_737] . In stratum 1, 
patient numbers will be assigned sequentially  per investigative site, beginning with 101. In 
stratum 2, patient numbers will be assigned sequentially  per investigative site, beginning with 
201. In the safet y expansion phase, patient numbers will be assigned sequentially  per 
investigative site, beginning with 301 in stratum 1 and 401 in stratum 2. S ubsequent patients 
enrolled in each phase of the study  will be assigned consecutive patient ID numbers per phase 
and per site (e.g. the second patient at a site in a specific phase will be assigned patient
number 102/202/302 /402, the third patient will be assigned patient number 103/203/303 /403, 
etc).
Only  the assigned patient ID number should be entered in the 
field labeled as “patient
number ” on the EDC data entry  screen. Once assigned, the patient number must not be re-
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879312]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879313]

[COMPANY_001] / Incyte Corp. Confidential Page 40
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
used for any other patient and the patient number for that individual must not be changed, 
even if the patient is re- screened.
If the patient fails to be started on treatment for any reason, the reason and the patient’s 
demograph y information should be collected. N o other data will be entered into the clinical 
data ba se for screen failure patien ts.
3.1.5 Treatment assignment/randomization
Prior to patient signing of the informed consent form (I CF), the Investigator smust contact [CONTACT_655154].
The assignment of a patient will be coordinated by [CONTACT_655155].
3.1.6 Treatment blinding
Not applicable. This is an open label stud y.
3.2 Rationale for the study  design
For a significant population of thrombocy topenic MF patients there are limited data about the 
safet y of INC424 or what might be an appropriate dose. In all studies conducted to date with 
INC424, baseline PLT count of ≥ 100 x109/L has been an inclusion criterion. However, 
thrombocy
topenia is a frequent event in MF; as per epi[INVESTIGATOR_655129] (Mesa et al 2007) , 
16.5% of all MF patients are reported to have PLT counts < 100 x109/L at diagnosis, while in 
the intermediate risk-1, -2 or high- risk disease population the incidence of thromboc ytopenia 
is estimated by  [CONTACT_655156]. As noted in Section 1.2.4 , thrombocytopenia was 
established as the DLT of INC424 in MF patients with a MTD of both 25 mg b.i.d. and 100 
mg qd. In that study , some patients continued to receive INC424 while their platelet count 
ranged between 50 and 100 x109/L(for details, see Section 3.4.5) , but no patients with platelet 
counts below 100 x109/L have initiated INC424 therapy , and therefore the MSSD for patients 
with low platelets needs to be directl y established.
Thisclinical trial will be a single arm, safety  and dose-finding phase Ib study . It will evaluate 
the safet y of INC424 in the low-PLT MF population and will establish the MSSD . Gradually  
increasing doses of INC424, ranging from 5 mg b.i.d. to 15 mg b.i.d., 
will be used in the dose 
escalation part of the study . Initiall y, only patients with PLT counts 75-99 x109/L (first 
stratum) will allow to be enrolled. Once 
safet y in patients in the first stratum is established at 
the first two dose cohorts (5 mg b.i.d. and 5 mg q.AM / 10 mg q.PM) the eligible population 
will be further expanded to patients with PLT counts 50
-74 x109/L (second stratu m).
Following determination of the MSSD , thesafety  expansion phase will be conducted. In the 
safet y expansion phase ,the safet y and tolerability  of the MSSD will be further evaluated, with 
the purpose of establishing that this dose is suitable for use in the low-platelet population of 
patients with MF. Moreover, estimates of efficacy will be obtained.
3.3 Purpose and timing of interim analy ses/design adaptations
A Bayesian logistic regression model will be used to assist patients’ assignment to treatment 
dose levels and to guide dose escalation decisions. The dose -finding part of the study  requires 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879314]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879315]

[COMPANY_001] / Incyte Corp. Confidential Page 41
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
data to be reviewed after each cohort is completed in order to determine the best dose for the 
next cohort of patients.
An interim analy sis is planned at the time the MSSD is declared and all patients in the dose 
escalation phase have completed the core study period. The interim analy sis will include 
primary  and secondary  endpoints of safet y and efficacy .Full PK data will be available at the 
time of the interim analysis and the results will be reported in a separate PK report.
3.4 Rationale for the dose/regimen selection and treatment duration
3.4.1 Clinical safety  and tolerability
[IP_ADDRESS] Healthy  volunteers
INC424 has been administered in single or multiple doses to over 200 healthy  volunteers. In 
single dose studies, INC424 has a well established safet y profile and has been well tolerated 
with AEs generally  mild in intensity , reversible and of similar incide nce following INC424 
treatment compared with placebo or with other control treatments. INC424 was examined in a 
10-day multiple dose study  in a total of 71 healthy volunteers in 6 cohorts who received doses 
of 50 mg qd, 100 mg qd, 15 mg b.i.d., 25 mg b.i.d.or 50 mg b.i.d.of INC424 or placebo
(study [INCB [ZIP_CODE]- 132]) . INC424 was well tolerated in the study , with most Adverse 
Events reported equally  by [CONTACT_655152]424 -treated and placebo-treated volunteers. Neutropenia, 
as an AE, was noted in [ADDRESS_879316] dose of INC424, 50 mg bid. 
Neutropenia at the grade 4 level led to study  drug discontinuation on Day 5 in one volunteer, 
and was reported as a SAE. There was a decline in mean ANC and to a lesser extent, mean 
WBC values with INC424 doses of 15 mg b.i.d.or higher. In general, these declines in ANC 
or WBC were observed early during the 10
-day dosing period with b.i.d. regimens; did not 
worsen with continued dosing, and returned to baseline levels within [ADDRESS_879317]. Doses of 25 mg b.i.d.
and 100 mg qd were determined to be the maximum tolerated doses in this study . For 
additional details related to these studies, consult the IB.
A definitive QT study: An Asse ssment of Heart Rate Corrected QT Intervals in Health y 
Subjects Dosed with Single Doses of INC424 Compared with Moxifloxacin 
([INCB18424-138] ) was carried out in 50 healthy  volunteers, evaluating the effects of single 
doses of 25 mg or 200 mg INC424 compared with placebo and 400 mg moxifloxacin (positive 
control). The results showed little change in the mean heart rate, QRS duration, or QTcF 
duration indicating a lack of a drug effect.  
 Aslight increase in PR interval the first hour after dosing was noted, but 
unlikely  to be clinically significant in the opi[INVESTIGATOR_655130]. The overall 
conclusion is that there appears to be no adverse impact on ECG signaling with the 
administration of INC424.
[IP_ADDRESS] Myelofibrosis patients
INC424 , in the context of the [INCB [ZIP_CODE]-251] study  (refer to Section 1.2.4), has been well 
tolerated by [CONTACT_655157]. Most adverse events were mild to 
moderate in severit y, considered unrelated to study  drug administration and not dose 
dependent. Related adverse 
events occurring in at least 8 patients (5%) included in the safet y 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879318]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879319]

[COMPANY_001] / Incyte Corp. Confidential Page 43
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
CYP3A4 based on in vitro studies. Nearly  100% of INC424 is metabolized by  [CONTACT_4852], while 
nearl y zero metabolism occurs in the kidney . The kidney  is an organ of INC424 excretion and 
does not metabolize I NC424
Elimination: Following a single oral dose of 25 mg [14C]-labeled INC424 in health y adult 
volunteers, the recovery  of the administered radioactivity  was 95.53 ± 4.93%, with 73.61 ± 
10.18% and 21.92 ± 5.95% in urine and feces, respectively ; indicating that urine was the 
major route of excretion for INC424 -related radioactivit y. Parent compound was the 
predominant entity  in circulation, representing 57% of total radioactivity . The mean 
elimination half -life of INC424 is approximately  3 hours.
[IP_ADDRESS] Healthy  volunteers
In healthy  volunteers INC424 absorption is rapid, mean peak plasma concentrations are 
achieved [ADDRESS_879320] dose. Single dose exposure (C maxand AUC) increased proportionately 
with dose (range 5 mg to 200 mg). The mean terminal phase elimination half-life was 
approximately  [ADDRESS_879321] slowed the absorption (mean T maxincreased from 1.3 to 2.7 h), and reduced 
the mean Cmaxby 24% without significant effect on area under the curve, of a 25 mg INC424 
tablet.
In healthy  volunteers dosed orally  with 14C-INC424, unchanged INC424 was the predominant 
circulating drug-related entity  with two major circulating metabolites observed, both of which 
are mono -oxidation products. 75% of total radioactivity  was recovered in urine, while 
recovery  of parent was minimal. The metabolites of INC424 are pharmacologicall y active 
with varying degrees of activity  on JAK kinases. The two metabolites with the highest 
exposure as a fraction of the parent, 30% and 14%, exhibit IC50values for inhibiti on of IL6 
stimulated pSTAT3 in human whole blood that is ≥ 3-4 fold higher than the parent (280 nM). 
This in vitro estimate for INC424 is in good agreement with the IC50(225 nM) estimated ex 
vivo with data collected in a multiple dose volunteer study .
[IP_ADDRESS] Special population
Elderly :No overall differences in safety , effectiveness, or pharmacokinetics of INC424 were 
observed between elderl y and younger patients.
Renal 
Insufficiency: Following a single INC424 dose of 25 mg, the pharmacokinetics were 
similar in patients with various 
degrees of renal impairment and in those with normal renal 
function. INC424 is not removed by [CONTACT_2900]. Patients with end stage renal disease on dialysis 
had prolonged pharmacod ynamic activity  (inhibition of IL-6 stimulated STAT3 
phosphory lation in whole blood). Patients with severe kidney  disease (MDRD -eGFR < 30 
mL/min/1.73m2) or on dialy sis will be excluded from this study .
Hepatic Insufficiency: Following a single INC424 dose of 25 mg in patients with varying 
degrees of hepatic impairment (8 patients per group), the pharmacokinetics and 
pharmacod ynamics of INC424 were assessed. There was no rank order correlation between 
exposure and degree of hepatic impai rment assessed by [CONTACT_2751]-Pugh scores. The mean AUC 
for INC424 was increased in patients with hepatic impairment by [CONTACT_2902] 88%, 29% and 66% 
respectivel y, in patients with mild, moderate and severe hepatic impairment compared to 
patients with normal hepatic function. INC424 pharmacod ynamic activity  (inhibition of IL-6 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879322]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879323]

[COMPANY_001] / Incyte Corp. Confidential Page 46
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
During the dose escalation phase, the following dose levels are planned to betested with 
regards to safet y, particularl y:
5 mg q.AM / 5 mg q.PM
5 mg q.AM / 10 mg q.PM
10 mg q.AM / 10 mg q.PM
10 mg q.AM / 15 mg q.PM, and
15 mg q.AM / 15 mg q.PM.
Twice dailyschedule ispreferred to once dailyposology for 
this study ,because the phase II 
data from [INC18424- 251] study  demonstrate dbetter efficacy  with this schedule. The phase 
III trials , [INC18424- 351] and [INC18424-352] ,also use twice daily  schedules for the same 
reason.
The highest INC424 dose allowed in the study  will be 15 mg b.i.d.Further dose escalation 
beyond the 
MSSD ,foradditional clinical benefit, although will not be tested in this study , 
may be feasible in selected MF patients presenting with thrombocy topenia and could be 
explored in another clinical tri al.
3.5 Rationale for choice of combination drugs
Not applicable.
3.6 Rationale for choice of comparators drugs
Not applicable.
3.7 Sub-studies
Not applicable.
3.8 Definition of end of the study
The End of the Study  (Last Patient Last Visit, LPLV) will occur after all patients in the study 
have completed their last assessment as per protocol. Patients who are benefiting from study 
drug may continue study treatment for the duration of 3 years unless one or more withdrawal 
criteria (Section [IP_ADDRESS]) are met and if the treatment with INC424 is considered the patient’s 
best therapeutic option by  [CONTACT_737].
[The above paragraph will read as follows for the [LOCATION_008] onl y:
The End of the Study  (Last Patient Last Visit, LPLV) will occur after all patients in the study 
have completed their last assessment as per protocol. Patients who are benefiting from study 
drug may continue study treatment for 3 years if the treatment with INC424 is considered the 
patient’s bes t therapeutic option by  [CONTACT_737]. 
After [ADDRESS_879324] access to study  drug outside of this clinical trial, the patient 
may continue 
on study  treatment until LPFV plus 3 years. After LPFV plus 3 years, if the 
study  treatment is not commerciall y available and reimbursable in the [LOCATION_006], an alternative [LOCATION_006]-
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879325]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879326]

[COMPANY_001] / Incyte Corp. Confidential Page 48
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
Patients enrolled in the study  cannot participate in any concurrent clinical study  investigating 
other investigational agents or devices. Patients who have completed or discontinued the 
study  may  not be re -enrolled in the study  for a second course of treatment.
The Investigator or designee must ensure that only patients who meet all the following 
inclusion and none of the exclusion criteria are offered enrollment in the study . All data for 
selection criteria must be verifiable in the patient’s source documents.
A written Informed Consent Form (ICF) must be obtained before the start of any screening 
procedure . For screening procedures refer to Section 6.1.[ADDRESS_879327] to meet all of the following criteria:
1.Patients [ADDRESS_879328] be diagnosed with PMF, PPV
-MF or PET -MF irrespective of 
, guided by  [CONTACT_488265] 2008 World Health Organization 
(WHO) criteria for PMF (Table 2 in Tefferi and Vardiman, 2008, Appendix 1a ), and the 
proposed criteria for PPV -MF and PET -MF outlined by  [CONTACT_655158] M yelofibrosis Research and Treatment (IWG -MRT) (Table 1 in Barosi et al, 2008, 
Appendix 1b).
3.Patients with my elofibrosis requiring therap y must be classified at least as intermediate 
risk level 1 (1 or more prognostic factors). The prognostic factors, defined by  [CONTACT_374758] ( Cervantes et al 2009 )are:
age > 65 yrs
presence of constitutional sy mptoms ( weight loss > 10% in the year preceding 
the 
Screening Visit , unexplained fever, or excessive night sweats persisting for more than 
1 month )
marked anemia (Hgb < 10g/dL)*
leukocy tosis (history  of WBC > 25 x109/L)
circulating blasts ≥ 1%
A hemoglobin value < 10 g/dL must be demonstrated during the Screening for 
patients who are not transfusion dependent. Patients receiving regular transfusions of 
packed red blood cells will be consi dered to have hemoglobin < 10 g/dL for the 
purpose of evaluation of risk factors
4.Patients must have palpable spleen of at least [ADDRESS_879329] 5 (0- 10 point scale) or two sy mptom scores of at least 3 (0 to 10 point scale) on the 
Screening S ymptom Form, SSF ( Appendix 2 )
6. Patients must fulfill all the following criteria at Screening or at Study  Day  1:
PLT counts < 100 x 109/L and ≥ 75 x 109/L for the first stratum of the trial or PL T 
counts < 75 x 109/L and ≥ 50 x 109/L for the second stratum
coagulation parameters as follows: INRand PTT < 1.5 x UL N
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879330]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879331]

[COMPANY_001] / Incyte Corp. Confidential Page 49
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
7.Patients with ANC > 1 x 109/L at Screening
8. Patients with peripheral blood blast count of < 5% at Screening
9.Patients with an ECOG performance status of 0, 1, or 2 at Screening (Appendix 11 )
10.Patients must have discontinued all drugs used to treat underl ying MF disease no later 
than [ADDRESS_879332] notmeet any of the following criteria:
1. Pregnant or nursing (lactating) women
2.Women of childbearing potential who are unwilling to take appropriate precautions (from 
Screening through Follow- up) to avoid becoming pregn ant
Females of non-childbearing potential are defined as women who (a) are ≥ 55 y ears of 
age with history  of amenorrhea for 1 y ear with serum FSH levels > 40 mIU/mL , OR
(b) are surgically  sterile for at least 12 weeks
For females of childbearing potential, appropriate precautions (at least two highl y 
effective contraception
methods) are those that are at least 99% effective in 
preventing the occurrence of pregnancy. These methods should be communicated to 
the patients and their understanding confirmed ( Appendix 3 )
3.Patients undergoing treatment with hematopoietic growth factor receptor agonists (i.e. 
erythropoietin (EPO), granulocy te colony  stimulating factor (GCSF), romiplostim, 
eltrombopag) for at least 30days prior t o receiving the first dose of study  drug
4.Patients with any  history  of PL T counts < 45 x 109/Lwithin [ADDRESS_879333] receive dPLT transfusion within 14 day s
prior to Screening evaluations.
5.Any history  or predisposition to clinically  significant bleeding
6.Any history  of platelet dy sfunction and/or bleeding diathesis
7.Any regular use of drugs that interfere swith coagulation or inhibits PL T function
(Appendix 4 ).
NOTE: l ow doses of aspi[INVESTIGATOR_248] ≤ 125 mg/day  are allowed.
8.
Patients with inadequate liver or renal function as demonstrated b y:
encephalopath y grade 1or more ,as per West Haven Criteria ( Appendix 5 )
known hepatocellular disease (e.g. active hepatitis or cirrhosis)
total bilirubin ≥[ADDRESS_879334] bilirubin ≥ [ADDRESS_879335]
alanine aminotransferase (ALT) > 2.5x ULN
MDRD -eGFR < 
30 mL /min/1.73m2or on dialy sis (Appendix 6 )
9.Patients with clinically  significant bacterial, fungal, parasitic or viral infection which 
require therap y. Patients with acute bacterial infections requiring antibiotic use should 
delay  screening/enrollment until the course of antibiotic therapy  has been completed
10. Patients with known active hepatitis A, B or C at Screening or with known HIV positivity
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879336]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879337]

[COMPANY_001] / Incyte Corp. Confidential Page 50
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
11.Patients being treated concurrentl y with a potent systemic inhibitor or a potent sy stemic 
inducer of CYP3A4 at the time of Screening ( see Appendix 7 )
12.Patients with impairment of gastrointestinal (GI) function or GI disease that may  
significantl y alter the absorption of oral INC424 (e.g., uncontrolled nausea, vomiting, 
diarrhea, malabsorption sy ndrome, small bowel resection)
13.Patients who currentl y are candidate sfor a stem cell transplantation at the time of the 
screening assessments
14.Patients with an active malignancy  over the previous [ADDRESS_879338] 3 y ears
15.Patients with currentl y rapid or parox ysmal atrial f ibrillation, currentl y uncontrolled or 
unstable angina, recent (approximately  6 months) my ocardial infarction or acute coronary  
syndrome or an y clinically significant cardiac disease (NYHA Class III or IV; 
Appendix 8)
16.
Patients under ongoing treatment with another investigational medication or having been 
treated with an investigational medication within 30 day s or 5 half -lives (whichever is 
longer) prior to enrollment
17.Patients who have had splenic irradiation within 12 months prior to Screening
18.Patients who are unable to comprehend or are unwilling to sign a n informed consent form
19.Patients with active alcohol or drug addiction that , in the investigator’s expert judgment,
would interfere with their ability  to compl y with the study  requirements
20.Patients with any  concurrent condition that, in the Investigator ’s opi[INVESTIGATOR_1649], would 
jeopardize the safet y of the patient or compliance with the protocol
21.Patients who cannot operate electronic diary  equipment, or who cannot read the screen or 
who cannot speak or read and understand the languages provided with the diary  (as per e -
diary  vendor manual)
22.Subject with a life expectancy  of less than [ADDRESS_879339] eCRF.
5.1.1 Administration
Table 5-1 Treatment and treatment schedule
Study 
treatmentPharmaceutical form and 
route of administrationDose Frequency
INC424 Tablets for oral use Starting dose 5 mg to be increased 
or decreased (5 mg steps) per 
Bayesian design (see Section 5.1.2 )b.i.d. (approximately 12 
hours apart: morning 
and night)
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879340]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879341]

[COMPANY_001] / Incyte Corp. Confidential Page 51
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
Patients will self-administer INC424 tablets as instructed (see Table 5-1and Section 5.1.2). If 
the patient forgets to take adose, then he/she should take INC424 within [ADDRESS_879342] carry the diary  with them at each Study  Visit so as the data to be captured by [CONTACT_655159] ( Tabl
e 6-1and Table 6 -3).
Patients will not take the morning dose of INC424 on the Study  Days 1 and 15for their timed 
PK assessment ( seeTable 6 -
4); study  drug will be administered in the clinic in order to obtain 
post-dose plasma levels of INC424 (Section 6.2.3 ).On all other days corresponding to Study 
Visits, patients will take the morning dose of s tudy drugs prior to the visit.
5.1.2 Dosing and treatment schedule
INC424 tablets will be administered b.i.d. (approximately  12 hours apart: morning and night) 
orally , with at least [ADDRESS_879343] to food, in an 
outpatient setting .
The dosage strength is 5 mg/tablet INC424 phosphate (free base equivalent). Patients will 
begin dosing on a b.i.d. schedule.
In the dose escalation phase, the starting dose will be 5 mg b.i.d. and the 
maxi mum dose will 
be 15 mg b.i.d. , if MSSD is not reached at a lower dose. An adaptive Bayesian logistic 
regression model guided by [CONTACT_655160]. The dose-escalation cohorts will be:5 mg q.AM / 5mg q.PM , 5mg q.AM / 
10mg q.PM, 10 mg q.AM / 10mg q.PM, 10mg q.AM / 15mg q.PM, and15mg q.AM / 15
mg q.PM (see Table 5 -
2).
Following determination of the MSSD , a safet y expansion phase will be conducted. Patients 
from both strata can be enrolled simultaneousl y during the safety  expansion phase. If the 
MSSD is the same in both strata, all patients in the safet y expansion phase will be treated with 
the same dose, regardless of the b aseline PLT counts (see Section 5.1.3).
[IP_ADDRESS] Starting dose level for cy cle 1
INC424 will be dosed on a flat scale of mg/day (b.i.d. )and not individually  adjusted by 
[CONTACT_565301]. In the dose escalation phase of the study , 
the starting dose, for 
both strata, will be 5 mg q.AM / 5 mg q.PM. INC424 t ablets of 5 mg are available.
[IP_ADDRESS] Dose escalation levels
Table 5
-2 Dose levels
Dose levels
Dose level 1 5 mg q.AM / 5 mg q.PM
Dose level 2 5 mg q.AM / 10 mg q.PM
Dose level 3 10 mg q.AM / 10 mg q.PM
Dose level 4 10 mg q.AM / 15 mg q.PM
Dose level 5 15 mg q.AM / 15 mg q.PM
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879344]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879345]

[COMPANY_001] / Incyte Corp. Confidential Page 52
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
Doses will be administered according to the dose escalation schedule listed in Table 5 -2.Dose 
escalation will continue until MSSD is reached.
[IP_ADDRESS] Criteria for dose escalation and determination of MSSD
The primary  analysis method is an adaptive Bayesian logistic regression model guided by 
[CONTACT_655161] (Babb 1998). To make decisions about escalation to the next 
dose level, 
the Investigator sand the Sponsors study  personnel (including the study  physician, 
a safet y physician and a statistician) will evaluate the available clinical and laboratory  data (of 
all patients participating in the study ,in all dose levels regardless duration) , the toxicity  
information (including adverse events that are not DLTs) and the recommendations from the 
BLRM at a dose-escalation decision meeting or teleconference (T/C) .Regarding 
thrombocy topenia, not only absolute PLT values, but also the speed at which the PLT counts 
decline will be taken into account for dose-escalation or dose-modification decisions. PK 
analysis data will not be a factor considered during this dose escalation decision process. The 
meetings should be conducted according to Sponsor s’ Standard Operating Procedur esand 
further details will be provided in the Study  Manual. Both Sponsors ’study  personnel 
([COMPANY_001] Pharmaceuticals and Incyte Corporation) must be in agreement for dose-escalation 
decisions and/or MSSD declaration. Drug administration at the next dose level may not 
proceed until the Investigator sreceive written confirmation from the Sponsors that the results 
of the previous dose levels were evaluated and it is safe to proceed to a higher dose level.
Criteria for dose escalation are provided in the Section 3.1and Section 9.4.[ADDRESS_879346] closely  associated with a posterior DLT probability  of between 16% 
and 33% that does not al so have 
a greater than 25% probability  of excessive toxicity .
In case the MSSD cannot be established due to lack of toxicity atthe dose levels tested , the 15 
mg b.i.d. dose will be the proposed dose for the patients in the safet y expansion phase.
[IP_ADDRESS] Dose escalation
A prior distribution for the model parameters is derived based on experience with INC424 in 
adult patients in clinical study  [INCB [ZIP_CODE]- 251], which was the dose-finding study  in 
patients with my elofibrosis that preceded the pi[INVESTIGATOR_655131] ,[INCB [ZIP_CODE]-351] and 
[INCB [ZIP_CODE]
-352] (see Section 1.2.4). The model will then be updated after each cohort of 
patients in each stratum with the DLT data from the current study . A detailed description of 
the methodology  can be found in Section 9.4.2.
The first [ADDRESS_879347] be enrolled from stratum 1 (patients with 
baseline PLT counts 75-99 x109/L). These [ADDRESS_879348] dose level
(dose level 1 , Table 5 -2). At least 3 evaluable patients are n eeded per dose level to make dose 
escalation decisions. The previously  mentioned (see Section 
[IP_ADDRESS] ) BLRM with EWOC will 
be updated after all patients in a cohort become evaluable (for the dose-determ ining analy sis 
set) or discontinue therapy . The dose-determining set (DDS) , as defined in Section 9.1.3,
consists of all patients from the safet y set who either (a) meet the minimum exposure criterion 
a
nd have sufficient safety  evaluations or (b) discontinue due to DLT. Decisions to escalate 
will be in accordance with satisfying the overdose control criterion based on the results of this 
modeling , and will be implemented after a joint teleconference or meeting between 
Investigators and Sponsors, as described in Section [IP_ADDRESS] .As an exception, if the first 2 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879349]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879350]

[COMPANY_001] / Incyte Corp. Confidential Page 53
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
patients in the cohort experience DLT before the enrollment of the 3rdpatient, the model will
be re -evaluated before enrollment of an y additional patients to the cohort.
Enrollment will begin in stratum [ADDRESS_879351] 6 patients from stratum 1 are 
confirmed to be in the dose-determining set (DDS) and dose level 3 is allowed for enrolment 
in stratum 
1, then patients from stratum 2 (patients with baseline PLT counts 50-74 x109/L) 
may be enrolled at the first dose level. For the subsequent dose levels, patients in stratum [ADDRESS_879352] be 
treated at the dose declared to be the MSSD , for each stratum.
[IP_ADDRESS] Safety  expansion phase
Once the MSSD of INC424 is identified for both strata in the dose escalation phase of this 
study , additional patients will be enrolled and treated at this dose in order to further evaluate 
its safety andtolerability and to obtain estimates of efficacy , with the purpose of establishing 
that this dose is suitable for use in the low-platelet population of patients with MF. Patients 
from both strata canbe enrolled simultaneousl y during the safety  expansion phase. If the 
MSSD is identical in both strata, all patients in the safet y expansion phase will be treated with
the same dose. Prior to Amendment 4, 
twent y patients (10 patients from each stratum), in 
addition to the patients treated at the MSSD during the dose escalation phase, were to be 
evaluated during this part of the study . If the MSSD proves not to be well tolerated with 
further experience and via continuous update of the Bay esian logistic regression model during 
this safety  expansion phase, then a lower dose may be evaluated to twent y additional patients 
(10 patients from each stratum).
With the approval of Amendment 4, all new patients enrolled to Stratum 1’s safet y expansion
phase will be given the [ADDRESS_879353] Patient’s 
First Visit (LPFV) will occur on [ADDRESS_879354].  Patients alread y 
taking the 15 mg BID dose in Stratum 1’s safet y expansion phase will continue to take their 
assigned dose.   Stratum 2 will maintain its original enrollment requirement of 10 patients at 
the MSSD.
The criteria for continuation of treatment and dose modification guidelines employ ed during 
the dose escalation phase will also be followed during safet y expansion phase .Dose
escalation above the MSSD will not be allowed.
[IP_ADDRESS] Dose cohort modification
Dose level cohorts are listed in Table 5-2. Possible changes in dose administration according 
to the BLRM include ,but are not limited to ,(a) expansion of the current dose group to further 
assess suspected treatment
-related adverse events, (b) termination of any further escalation of 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879355]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879356]

[COMPANY_001] / Incyte Corp. Confidential Page 54
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
study  drug.Investigators will receive written confirmation from the Sponsors notify ing them 
that enrollment has been increased or decreased, or that no further enrollment will occur.
[IP_ADDRESS] Intra -patient escalation
Intra -patient dose escalation will only be permitted after Study  Day 56. During the course of 
the study , 
patients can be dose-escalated to the next higher dose level only once every  two 
cycles(each cy cle is 28 day s), provided that ALL of the following criteria are met:
inadequate efficacy  is seen with the current dose level, as defined by  [CONTACT_655162]:
not achieving at least a 50% reduction in palpable spleen length compared to Study  
Day 1
lack of meaningful improvement in disease s ymptoms based on the Investigator’s 
expert judgment.
no treatment -related toxicity  has occurred with the current dose level, resulting in 
treatment reduction or interruption or discontinuation in the previous [ADDRESS_879357] 24 weeks of treatment foran individual patient, the dose-escalation requir ements 
will be as follow s
:
the maximum dose with which the patient is to be treated does not exceed [ADDRESS_879358] 3 patients for a minimum of 28 day s in that stratum, with 
no more than 1 out of 3 patients experiencing DL T
the minimum PL T count during the first 24 weeks period is ≥ 50 x109/L OR ≥ 75% of the 
baseline PLT count the current dose level is lower than the MSSD .
For treatment bey ond the first 24 weeks, the dose -escalation requirements will be as follows:
the maximum dose with which the patient is to be treated is the higher of :the MSSD 
established for that stratum OR 10 mg bid
the minimum PL T count at the time of the escalation is ≥ 50 x109/L AND is ≥ 75% of the 
baseline PLT count if a patient experience da PLT count ≤ 50 x109/L OR≤ 75% of the 
baseline PLT count beyond the first [ADDRESS_879359] T count ≤ 50 x109/L or ≤ 75% of 
the baseline PLT count (if it is suspected to be drug related), no further dose escalation 
will be allowed.
The rules for intra-patient escalation described above are also applicable to patients who have 
undergone one and only one dose reduction. Conversel y, dose reduction rules (described in 
theSection 
5.1.3 )also apply to patients who undergo dose escalation. Once a patient 
undergoes a dose reduction due to treatment -related toxicity , the patient may not have a dose 
increase unless they  have been on a stable dose for at least [ADDRESS_879360] experienced treatment -related ≥ grade [ADDRESS_879361] every  second week for the next 4 weeks. Thereafter, they  may  resume 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879362]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879363]

[COMPANY_001] / Incyte Corp. Confidential Page 55
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
monthly  evaluations. Further recommendation can be given during the T/C meetings, on an 
individual ba sis.
Consultation with the Sponsors must occur prior to any  intra -patient dose escalation.
[IP_ADDRESS] Dose -limiting toxicity (DLT)
Dose -limiting toxicity  (DLT) will be defined as the occurrence of any of the treatment -
related toxicities occurring up to and including Study  Day 28, which are listed inTable 5-3, 
using the 
Common Terminology  Criteria for Adverse Events ( CTCAE )v4.03.
For the purpose of dose-escalation decisions, only DLTs will be necessarily  considered and 
included in the BLRM. However, adverse events ,which occur after Study  Day28and meet 
all the criteria for the DLT definition apart from the timing of occurrence, willbe considered 
in ultimate decisions of dose escalat ion and determinations of how many patients should be 
evaluated at a given dose level. Prior to enrolling patients into a higher dose level, all adverse 
events will be reviewed for all patients at the current and the previous dose levels.
For toxicities which, by [CONTACT_108], require a time-window for them to be defined as DLTs 
(grade 3 
non-hematologic toxicity  for ≥ 7 consecutive days),a subsequent visit(s)and/or 
laboratory  assessment (s)must be scheduled accordingl y, in order for this toxicity  to qualify as 
a DLT.For example, if a grade [ADDRESS_879364] 7 day s later, with no intervening lower grades, in order to qualify  as a DLT.
Table 5
-3 Criteria for defining dose -limiting toxicities
Toxicity Any of the following treatment-related criteria (occurring through Study  Day 28)
Hematology PLT counts < 25x109/L*
grade 4 neutropenia (ANC < 0.5 x109/L)*
grade ≥ 3 febrile neutropenia *
Other AEs any grade thrombocytopenia requiring PLT transfusion
any grade ≥ 2 hemorrhagic event
grade ≥ 2serum bilirubin with coincident direct bilirubin ≥0.5 mg/dL
grade 3 non -hematologic toxicity for ≥ 7 consecutive days
grade 4 non -hematologic toxicity
* At the discretion of the Investigator, laboratory values can be confirmed with a second assessment. In this case, 
only the result of the second assessment will be considered valid and final.
Patients who experience a DLT will have their therapy  with INC424 interrupted and will be 
followed as described in the Table 5-4. After recovery  from the toxicity  in question, if the 
Investigator believ es that it is in the patient’s best interest to resume therapy  with INC424, the 
patient may resume therapy ,
only after consultation with the Sponsors , according to the 
guidelines described in the Section 5.1.[ADDRESS_879365] be permanentl y discontinued from study  medication and 
withdrawn from the study, if any of the following DL Ts occur:
any grade ≥ 3 hemorrhagic event
2ndepi[INVESTIGATOR_254335] ≥3 febrile neutropenia
grade 3 renal toxicity  for ≥ 7 consecutive days
grade 4 renal toxicity
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879366]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879367]

[COMPANY_001] / Incyte Corp. Confidential Page 56
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
grade [ADDRESS_879368] bilirubin ≥ 0.5 mg/dL
grade 4 non- hematologic toxicity
If, from Study  Day 1  through Study  Day 28, a patient misses > 6consecutive doses of 
treatment or > 20% of the planned study  drug doses, the patient will not be evaluable for 
DLTs. The 
patient can continue in the study , but another patient has to be enrolled at the same 
dose level and stratum in order to reach the required number of patients in the cohort .
[IP_ADDRESS] Follow -up for dose -limiting toxicities
Patients whose treatment is discontinued or interrupted due to aDLT, must be followed until 
resolution or stabilization of the DLT event, whichever comes first, as described in Section 
6.1.4.
In the case of PLT transfusion that is considered unrelated to the treatment wi th INC424 (e.g., 
car accident causing bleeding and subsequent PLT transfusion despi[INVESTIGATOR_655132] ≤ 3 
thrombocy topenia )
, then no measures should be taken, other than those related to the 
management of the event (Table 5-4). If the event for which the PLT transfusion was given is 
considered related to the treatment with INC424, then both the PLT toxicity -handling 
guidelines and the hemorrhagic event -handling guidelines should be taken into account.
In case of ahemorrhagic event of any grade (CTCAE grade 1 included) the Investigator is 
advised to perform coagulation tests and albumin assessment.
[IP_ADDRESS].1 Hematologic toxicity
In the case of grade 4 thrombocy topenia , assessment of PLT count is recommended to be 
repeated 
daily,Monday  through Friday , until resolution to grade ≤3 thrombocy topenia (it 
is at the I nvestigator’s discretion to perform PL T count assessments during weekends) . 
The subsequent follow -up should be done as described in Section 5.1.4 and in Table 6
-2.
In the case of grade [ADDRESS_879369] twice a week until resolution to grade ≤[ADDRESS_879370] preceding toxicity .Patients may be 
allowed dose reductions to 5 mg qd (dose level ( -1)). Dose reductions mo re than one level at a 
time will not be allowed, except for thrombocy topenia, in which case different rules for dose 
reductions apply (Table 5-4).Note that the maximum allowed doses are quoted in the partof 
Table 5-4where guidelines for dose reduction due to thrombocy topenia are provided; lower 
doses may be used at investigator discretion. It is recommended that patients who aredose 
reduc edfor thrombocy topenia have more frequent hematology  assessments. PLT counts must 
be obtained at least weekly  for [ADDRESS_879371] every  second week for the next 4 
weeks. Thereafter, they  may  resume monthly  evaluations.
Recovery  of platelet counts will a llow dose increases according to the guidelines in Table 5 -5. 
Note that once a dose is re-escalated , any subsequent declines in platelet count will require
that Table 5-4 be used to determine the new lower dose, or dose interruption.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879372]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879373]

[COMPANY_001] / Incyte Corp. Confidential Page 57
Amended Protocol Version 04 – Clean Protocol No. CINC424A2201
Dose level (-1)is the lowest acceptable dosing level for a patient participating in the study . If 
a patient cannot tolerate dose level (-1), then he/she must be discontinued from study
medication and withdrawn from the study  (see Table 5 -2for dose level definitions ).
Dose modifications for toxicities occurring during the DLT- definition period (Study  Day 1 
through Study  Day 28),and considered as treatment - related, will notbe allowed until the 
toxicity  qualifies as a DLT. After a toxicity  event has been characterized as a DLT, a patient 
can resume therapy  with a reduced INC424 dose according to the guidelines provided in the 
Section [IP_ADDRESS]. D ose modification recommendations after Study  Day 28are described in the 
Table 5-4.
Any dose modifications must be recorded on the Dosage Administration Record eCRF.
5.1.4 Treatment interruption and treatment discontinuation
Patients may continue treatment with INC424 for the duration of the study  oruntil they 
experience unacceptable toxicity  that precludes any further treatment, disease progression, 
and/or at the discretion of the Investigator . Patients will be discontinued from the study  if they 
withdraw consent, or if the treating physician judges that further therap y with INC424 is no 
longe r in the patient’s best interest.
Criteria for interruption and re-initiation of INC424 treatment are summarized in the Table 5-
4. A patient must discontinue treatment with INC424 if, after treatment isresumed at a lower 
dose, the same toxicity  recurs 
with the same or worse severit y. If a patient requires a dose 
delay  of > 28days, then the patient must be discontinued from the study . Patients who 
discontinue from the study  for a treatment -related adver se event or a treatment -related 
abnormal laboratory  value must be followed as described in Section 6.1.4.
Grading of toxicity  will be according to CTCAE Version 4.0 3.
Doses may be restarted and subsequently  increased, according to the Table 5-6, provided that 
platelet counts recover to ≥
35 x109/L andANC counts recover to ≥0.75 x109/L and there is 
no other toxicity that precludes dosing of the patient. Note that once a dose has been restarted, 
subsequent declines in platelet or ANC count will require that Table 5-4be used to determine 
the new lower dose or dose interruption. It is required that patients who have restarted dosing
have more frequent hematology  assessments. PLT and ANC counts must be obtained at least 
weekl y for [ADDRESS_879374] every  second week for the next 4 weeks. Thereafter, 
they may resume monthly  evaluations (exception: for grade 4 thrombocy topenia or 
neutropenia events please refer to Section [IP_ADDRESS].1
).
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879375]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879376]

[COMPANY_001] / Incyte Corp. Confidential Page 58
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Table 5-4 Criteria for interruption and re -initiation of INC424 treatment –Recommended dose modifications
Study  Day 1 through Stud y Day 28 Study  Day 29 to End of Treatment (EOT)
Worst Toxicity  
(CTCAE Grade 
unless otherwise 
specified)Treatment related toxicity Non-treatment related toxicity
Causality  of toxicity  and relation to the treatment with INC424 is based on the 
Investigator’s expert judgment
Hematological
Neutropenia
Grade 1
Grade 2
Grade 3
Grade 4Continue at s ame dose level
Continue at same dose level
Continue at same dose level
*Hold dosingContinue at same dose level
Continue at same dose level
Continue at same dose level
Hold dosingContinue at same dose level
Continue at same dose level
Continue at same dose level
Hold dosing
* qualifies as a DLT
In case of grade 4 neutropenia, follow -up rules according to Section [IP_ADDRESS].1 .
For dose restart guidelines, see Table 5 -6.
Grade ≥3 febrile 
neutro penia (ANC 
<1.0 x109/L, isolated 
fever ≥38.3°C or 
sustained fever 
>38°C for more than 
1 hour )* Hold dosing until resolved to afebrile 
neutropenia ≤ grade 2, then ↓ 1 dose 
level** †Hold dosing until resolved to afebrile 
neutropenia ≤ grade 2, then continu e at 
same dose level ‡Hold dosing until resolved to afebrile neutropenia ≤ 
grade 2, and:
if not related to INC424, then continue at same dose 
level***
if related to INC424, then ↓ 1 dose level***
* qualifies as a DLT
** Resume therapy according to the 
rules of Section [IP_ADDRESS] .
†If 2ndepi[INVESTIGATOR_1865], then discontinue‡If 2ndepi[INVESTIGATOR_1865], then discontinue *** If a second epi[INVESTIGATOR_254335] ≥[ADDRESS_879377] discontinue
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879378]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879379]

[COMPANY_001] / Incyte Corp. Confidential Page 59
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Study  Day 1 through Stud y Day 28 Study  Day 29 to End of Treatment (EOT)
Worst Toxicity  
(CTCAE Grade 
unless otherwise 
specified)Treatment related toxicity Non-treatment related toxicity
Causality  of toxicity  and relation to the treatment with INC424 is based on the 
Investigator’s expert judgment
Hemorrhagic event of any  kind
Grade 1
Grade 2
Grade 3
Grade 4Continue at same dose level
* Hold dosing until resolved completely, 
then ↓ 1 dose level
**Discontinue
**DiscontinueContinue at same dose level
Hold dosing until resolved completely, then 
continue at same dose level
Hold dosing until resolved completely, then 
continue at same dose level
Hold dosing until resolved completely, then 
↓ 1 dose level* **If not related to INC424, then continue at same dose 
level
If related to INC424, then h old dosing until resolved 
completely, then continue at same dose level
Hold dosing until resolved completely, and
if not related to INC424, then continue at same dose 
level
if related to INC424, then ↓ 1 dose level
Hold dosing until resolved completely, and
if not related to INC424, then continue at same dose 
level
if related to INC424, then discontinue
Hold dosing until resolved completely, and
if not related to INC424, then ↓ 1 dose level
if related to INC424, then discontinue
* qualifies as a DLT. Resume therapy 
according to the rules of Section [IP_ADDRESS] .
** qualifies as a DLT.*** the patient has to be substituted
In case of a hemorrhagic event of anygrade the Investigator is advised to perform coagulation tests and albumin assessment
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879380]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879381]

[COMPANY_001] / Incyte Corp. Confidential Page 60
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Study  Day 1 through Stud y Day 28 Study  Day 29 to End of Treatment (EOT)
Worst Toxicity  
(CTCAE Grade 
unless otherwise 
specified)Treatment related toxicity Non-treatment related toxicity
Causality  of toxicity  and relation to the treatment with INC424 is based on the 
Investigator’s expert judgment
Renal
Serum Creatinine
Grade 1
Grade 2
Grade 3
Grade 4Continue at same dose level
Continue at same dose level
Continue at same dose level, and
if duration ≥7 days*, then discontinue
* DiscontinueContinue at same dose level
Continue at same dose level
Hold dosing until resolved to ≤ grade 1, then 
continue at same dose level
Hold dosing until resolved to ≤ grade 1, then 
continue at same dose levelContinue at same dose level
If related to INC424, then either continue at same 
dose level orhold dosing until resolved to ≤ grade 1, 
then continue at same dose level†
If not relate d to INC424, then continue at same dose 
level
If related to INC424 **,then either continue at same 
dose level orhold dosing until resolved to ≤ grade 1, 
then continue at same dose level†. In any case, if 
duration ≥7 days, then discontinue .
If not related to INC424, then either continue at same 
dose level orhold dosing until resolved to ≤ grade 1, 
then continue at same dose level†,
If related to INC424, then discontinue
If not related to INC424, then hold dosing until 
resolved to ≤ grade 1, then continue a t same dose 
level* qualifies as a DLT
**If a second epi[INVESTIGATOR_254335] [ADDRESS_879382] 
discontinue
†at the discretion of the Investigator
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879383]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879384]

[COMPANY_001] / Incyte Corp. Confidential Page 61
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Study  Day 1 through Stud y Day 28 Study  Day 29 to End of Treatment (EOT)
Worst Toxicity  
(CTCAE Grade 
unless otherwise 
specified)Treatment related toxicity Non-treatment related toxicity
Causality  of toxicity  and relation to the treatment with INC424 is based on the 
Investigator’s expert judgment
Hepatic
Total bilirubin
Grade [ADDRESS_879385] Bilirubin < 0.5 mg/dL, then 
continue at same dose level
If Direct Bilirubin ≥ 0.5*, then hold 
dosing until Direct Bilirubin < 0.5 mg/dL, 
then ↓ [ADDRESS_879386] Bilirubin < 0.5 mg/dL, then 
continue at same dose level
If Direct Bilirubin ≥ 0.5*, then discontinueContinue at same dose level
If Direct Bilirubin < 0.5 mg/dL, then continue 
at same dose level
If Direct Bilirubin ≥ 0.5, then hold dosing 
until Direct Bilirubin < 0.5 mg/dL, then 
continue at same dos e level
If Direct Bilirubin < 0.5 mg/dL, then continue 
at same dose level
If Direct Bilirubin ≥ 0.5, then discontinue**Continue at same dose level
If Direct Bilirubin < 0.5 mg/dL, then continue at same 
dose level
If Direct Bilirubin ≥ 0.5, then hold dosing until Direct 
Bilirubin < 0.5 mg/dL, and
if not related to INC424, then continue at same dose 
level
if related to INC424, then ↓ [ADDRESS_879387] Bilirubin < 0.5 mg/dL, then continue at same 
dose level
If Direct Bilirubin ≥ 0.5, then disconti nue
* qualifies as a DLT. Resume therapy 
according to the rules of Section [IP_ADDRESS] .** the patient has to be substituted
Patients who develop new onset hepatic impairment (Direct Bilirubin ≥ 0.5 mg/dL) must have coagulation tests and albumin assessment .
Other adverse events
Grade 1 Continue at same dose level Continue at same dose level If related to INC424, then either continue at same 
dose level or↓ 1 dose level†
If not related to INC424, then continue at same dose 
level
Grade 2 Continue at same dose level Continue at same dose level
If related to INC424, then either continue at same 
dose level or↓ 1 dose level†
If not related to INC424, then continue at same dose 
level
Grade 3 Continue at same dose level, and:
if duration ≥7 days*, then hold dosing 
until resolved to ≤ grade 1, then ↓ 1 
dose levelHold dosing until resolved to ≤ grade 1, then 
continue at same dose level If related to INC424, then ↓ 1 dose level†
If not rela ted to INC424, then continue at same dose 
level
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879388]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879389]

[COMPANY_001] / Incyte Corp. Confidential Page 62
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Study  Day 1 through Stud y Day 28 Study  Day 29 to End of Treatment (EOT)
Worst Toxicity  
(CTCAE Grade 
unless otherwise 
specified)Treatment related toxicity Non-treatment related toxicity
Causality  of toxicity  and relation to the treatment with INC424 is based on the 
Investigator’s expert judgment
Grade 4 ** Discontinue Hold dosing until resolved to ≤ grade 1 or 
baseline grade , then continue at same dose 
levelIf related to INC424, then discontinue
If not related to INC424, then hold dosing until 
resolved to ≤ grade 1 or acceptable grade , then 
continue at same dose level
* qualifies as a DLT and r esume therapy 
according to the rules of Section [IP_ADDRESS] .
** qualifies as a DLT†at the discretion of the Investigator
Isolated values of CTCAE grade ≤ 3 alkaline phosphatase values will notrequire dose modification or interruption
Thrombocy topenia (PLT count at time of decline)
≥ 75 x109/L
50 -74 x109/L
35 -49 x109/L
25 -34 x109/L
< 25 x109/LContinue at same dose level
Continue at same dose level
Continue at same dose level
Continue at same dose level
* Hold dosing
* qualifies as a DLT. If resolved to ≤ 
grade 2, resume therapy according to 
the rules of Table 5 -6.Dose at the Time of the Platelet Decline
5 mg qd 5 mg 
b.i.d.5 mg q.AM / 
10 mg q.PM10 mg b.i.d. 10 mg q.AM / [ADDRESS_879390] be Instituted
Continue at same dose level
Continue at same dose level10 mg b.i.d.† 10mg b.i.d.†
Continue at same dose level‡
Continue at same dose 5 mg b.i.d. 5 mg b.i.d. 5 mg b.i.d. 5 mg b.i.d.
5 mg qd 5 mg qd 5 mg qd 5 mg qd 5 mg qd 5 mg qd
Discontinue Hold dosing
†Patients from stratum 1 ‡Patients from stratum 2
In cases of grade 4 thrombocytopenia, follow -up rules according to Section [IP_ADDRESS].1 .
For dose escalation or dose restart guidelines, see Table 5 -5and Table 5 -6.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879391]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879392]

[COMPANY_001] / Incyte Corp. Confidential Page 63
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Table 5-[ADDRESS_879393] previously decreased dosing for thrombocy topenia
Current Platelet Count Dose re -escalation guidelines (NOTE: maximum doses are 
given, lower doses may  be used at Investigator’s discretion)
25 x109/L -34 x109/L Continue at 5 mg qd until platelet counts ≥ 35 x109/L
35 x109/L -49 x109/L Continue at 5 mg b.i.d. u ntil platelet counts ≥ 50 x109/L
≥ 50 x109/L May increase dose by 5 mg qd each cycle (28 days) provided 
platelet count remains ≥ 50 x109/L,up to the dose where platelet 
counts first declined and dose reduction occur red
Table 5-[ADDRESS_879394] previously  interrupted dose for grade 4 thrombocy topenia or 
grade 4 neutropenia
Current platelet count Dose restart guidelines (NOTE: maximum doses are given, 
lower doses may  be used at investigator’s discretion )
<35 x109/L in a patient who is currently 
holding doseMust continue to hold
35 -49 x109/L in a patient who is recovering 
from a dose hold5 mg qd for 2 weeks, then increase in 5 mg qd increments, no 
faster than once every cycle (28 days), provided platelet counts ≥ 
50 x109/L
≥ 50 x109/L in a patient who is recovering 
from a dose hold5 mg b.i.d. for at least 2 weeks, then may proceed with 5 mg qd 
dose increases, no more frequently than once every cycle (28 
days), and provided platelets remain ≥ 50 x109/L, upto the dose 
where platelet counts first declined < 25 x109/L
Current ANC coun t Dose restart guidelines (NOTE: maximum doses are given, 
lower doses may  be used at investigator’s discretion )
<0.75 x109/L in a patient who is currently 
holding doseMust continue to hold
0.75 –1.00 x109/L in a patient who is 
recovering from a dose hold5 mg qd for 2 weeks, then increase in 5 mg qd increments, no 
faster than once every cycle (28 days), provided ANC counts >
1.00 x109/L
>1.00 x109/L in a patient who is recovering 
from a dose hold5 mg b.i.d. for at least 2 weeks, then may proceed with 5 mg qd 
dose increases, no more frequently than once every cycle (28 
days), and provided ANC remain >1.00 x109/L, up to a maximum 
dose of [ADDRESS_879395] 
declined < 0.50x109/L
NOTE: W hether the dose interruption occurred because of neutropenia, thrombocytopenia or both, when 
restarting, both the platelet count and ANC must be considered to determine the restart dose, with the lower 
calculated dose being used . Also, the maximum dose should always be [ADDRESS_879396] declined < 25 x109/L or ANC counts first declined < 0.5 x109/L.
5.1.5 Dose reduction of INC424 for concomitant CYP inhibitor u sage
INC424 is metabolized in the liver by [CONTACT_35233] (CYP) P450 metabolizing enzy me 
system, predominantly  by [CONTACT_941] 3A4 isozy me. With concomitant dosing of potent CYP3A4 
inhibitors such as systemic ketoconazole clarithromy cin, itraconazole, nefazodone and 
telithromy cin (Appendix 7), plasma exposure of INC424 increases approximately  2-fold. 
Patients under therapy  with a potent CYP3A4 inhibitor cannot be enrolled in the study . 
Use of 
CYP3A4 inhibitors during the study  is strongl y discouraged, and investigators should 
consider alternative therapi[INVESTIGATOR_577775]. However, if the use of a potent CYP3A4 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879397]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879398]

[COMPANY_001] / Incyte Corp. Confidential Page 64
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
inhibitor is necessary  for the sake of patient’s safet y, then a dose reduction of ~ 50% for 
INC424 is appropriate. The following dose -reduction rules should be foll owed:
If dose is 5 mg qd, treatment with INC424 has to be interrupted
If dose is 5 mg b.i.d., change dose to 5 mg qd
If dose is 5 mg q.AM / 10 mg q.PM, change dose to 5 mg qd
If dose is 10 mg b.i.d., change dose to 10mg qd
If dose is 10 mg q.AM / 15 mg q.
PM, change dose to 5 mg b.i.d.
If dose is 15 mg b.i.d., change dose to 15 mg q d
NOTE: once the course of therap y using a CYP3A4 inhibitor has been completed, the patient 
may resume his/her prior dose level of INC424 beginning the next day .
5.1.6 Optional dose ta pering strategy
 for INC424 in the event of 
discontinuation
When INC424 therap y is stopped, return of constitutional symptoms associated with elevated 
cytokines (e.g. night sweats, fever, fatigue) that had been suppressed while on therap y is 
expected. When a decision is made to permanently  discontinue INC424 therap y for reasons 
other than for hematologic safet y, a dose tapering strategy  may be considered, based on 
evaluation of the condition of the patient, current dosing regimen and the clinical judgment of
the Investigator , so that symptoms may return to pre-treatment condition more slowly .If 
considered to be medically  necessary , the Investigator may use any treatment to manage 
withdrawal from INC424 including a gradual tapering of the study  drug dosage or use of other 
medications to manage events occurring after discontinuation. Short- term courses of 
corticosteroids at doses > 10 mg/day  have been used in patients with MF and may be 
considered as part of a tapering strategy . Corticosteroids may  be started prior to, or concurrent 
with, INC424 tapering. When a decision has been made to discontinue the patient with 
utilization of a tapering strategy , regardless of the use of concomitant medications, safet y data 
will continue to be assessed in accordance with the protocol for a period of time as least 
through the continued administration on I NC424 and 30days after for AEs.
5.1.7 Rescue medication
Not applica ble.
5.1.8 Permitted concomitant therapy
The patient needs to notify  the investigati vesite about any  new medications he/she takes after 
the start of the study  drug. All medications (other than study  drug) and significant non-drug 
therapi[INVESTIGATOR_014] (including physical therap y and blood transfusions) administered after the 
patient
starts treatment with study  drug must be listed on the Concomitant medications/Significant 
non-drug therapi[INVESTIGATOR_655133].
5.1.9 Permitted concomitant therapy  requiring caution and/ or action
The following medications have restrictions on use or doses or require changes to the way in 
which INC424 is administered during the stud y:
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879399]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879400]

[COMPANY_001] / Incyte Corp. Confidential Page 65
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Systemic corticosteroid doses greater than the equivalent of 10 mg prednisolone per day  
arenot permitted, unless use is part of an INC424 -dose tapering strategy  (see 
Section 5.1.6).
During the study ,
the concomitant use of potent s ystemic CYP3A4 inhibitors is strongl y 
discouraged. However, when such a concomitant administration of a potent sy stemic 
CYP3A4 inhibitor (ketoconazole, clarithrom ycin, itraconazole, nefazodone and 
telithromy cin, see Appendix 7 ) is required for subject management, the dose of INC424 
must be adjusted as described in Section 5.1.5. Based on the low overall bioavailability  of 
topi[INVESTIGATOR_147063], with very  low s ystemic levels seen following topi[INVESTIGATOR_78086], 
no dose adju
stment of INC424 is needed for use with topi[INVESTIGATOR_147063]. No dose 
adjustments are necessary  when INC424 is co- administered with ery thromy cin, or by  
[CONTACT_66250], with other moderate or weak inhibitors of CYP3A4, including grapefruit juice 
(see Appendix 7 ).
During the study , the use of moderate CYP3A4 inducers (e.g., rifabutin, carbamazepi[INVESTIGATOR_050], 
and phen ytoin) is discouraged, and investigators should seek alternatives where possible. 
No dose adjustment will be used when m oderate CYP3A4 inducers are co- administered 
with I NC424. However, any  concomitant use of moderate CYP3A4 inducers (e.g., 
rifabutin, carbamazepi[INVESTIGATOR_050], pheny toin, see Appendix 7 ) must be documented .
Granulocy te growth fact ors are not allowed while study  medication is being administered 
but may  be used for severe neutropenia at the Investigator ’s discretion while study  
medication is being withheld.
5.1.10 Prohibited concomitant therapy
The following medications are prohibited durin g the study :
Any prior or concomitant use of another JAK inhibitor.
Any investigational medication (other than INC424) that is not approved for any  
indication. Use of such medications within [ADDRESS_879401] dose of study  drug and during the study  through the Safet y Follow -up 
Visit is prohibited.
Use of the potent inducers of CYP3A4 (such as rifampin and St John’s Wort), is not 
permitted at an y time during participation in the study (see Appendix [ADDRESS_879402] of 
CYP3A4 inducers).
Any regular use of drugs that interfere with coagulation or inhibit PL T function (except 
low dose saspi[INVESTIGATOR_248] ≤ 125 mg/day which are allowed ) and non -steroidal anti -inflammatory  
drugs (NSAIDs). For a complete list, see Appendix 4 .
Any other medication for my elofibrosis during the treatment period : hydroxy urea, 
busulfan, interferon, lenalidomide, thalidomide, anagrelide.
5.1.11 Hormonal contraception allowed/excluded
Females of childbearing potential will be requested to use the combination of two highl y 
effective contraception methods that have been determined to be at least 99% effective as 
indicated in Exclusion Criterion #2 (see Section 4.2 and Appendix 3 ).
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879403]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879404]

[COMPANY_001] / Incyte Corp. Confidential Page 66
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
5.2 Stud y drug(s)
5.2.1 Packaging and labeling
INC424 will be provided in bottles. Medication labels will be in the local language and 
comply  with the legal requirements of each country. They  will include storage conditions for 
the drug but no information about the patient .
Table 5-7 Packaging and labeling
Study drugs Packaging Labeling (and dosing frequency)
INC424 Tablets in bottle Labels with no reference to dosing
5.2.[ADDRESS_879405] ing to the 
instructions specified on the drug labels.
Table 5-8 Supply  and storage of study  drugs
Study drugs Supply Storage
INC424 Centrally supplied by [CONTACT_655163]
5.2.3 Dispensing and preparation
The study  medication packaging has a 2-part label. Investigator staff will add the patient
number on the label. Immediately  before dispensing the package to the patient, Investigator
staff will detach the outer part of the label from the packaging and affix it to the source 
document (Drug Label Form) for that patient ’s unique patient number.
Table 5-9 Dispensing and preparation
Study Drugs Dispensing Preparation
INC424 Tablets including instructions for administration are dispensed by [CONTACT_655164].
Patient s will be provided with adequate supply of study drug for self -
administr ation at home until their next scheduled study visit.Not applicable
5.2.4 Drug compliance and accountability
[IP_ADDRESS] Drug compliance
Compliance with the INC424 regimen will be calculated by [CONTACT_655165] y documented by [CONTACT_655166] -compliance 
diary  completed by [CONTACT_655167] /designee (pi[INVESTIGATOR_655134]). A patient will be considered 
sufficientl y compliant with INC424 treatment if they have taken at least 83.3% of their 
prescribed dose over the total duration of study  drug dosing.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879406]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879407]

[COMPANY_001] / Incyte Corp. Confidential Page 67
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
[IP_ADDRESS] Drug accountability
The Investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  drug in a drug accountabilit y ledger. Drug accountability  will be noted by [CONTACT_5364] . Patients will be asked to return 
all unused study  drug and packaging on a regular basis, at the end of the study  or at the time 
of study  drug discontinuation. Study  investigative site will need to keep used and unused 
study  drug for monitor to source verify  drug accountability .Patients will also be asked to 
complete the paper treatment -compliance diary  and carry  it with them at each Study  Visit.
At study  close-out, and, as appropriate during the course of the study , the Investigator will 
return all used and unused study  drug, packaging, drug labels, and a copy  of the completed 
drug accountability  ledger to the Sponsor smonitor or to the Sponsors address provided in the 
Investigator folder at each site.
5.2.[ADDRESS_879408] 
party,as appropriate , after drug accountabilit y.Any destruction of medication has to be 
approved / initiated b y the monitor.
[ADDRESS_879409] all of the 
assessments and indicate with an “X” the visits when they are performed. All data obtained 
from these assessments must be supported by [CONTACT_655168]’s source document. The 
table sindicate which data are entered into the database (D) and which data remain in source 
documents only (S) (column category ). Assessments that generate data for database entry  and 
which are recorded on eCRFs are listed using the eCRF name. Assessments that are 
transferred to the database electronicall y (e.g ., laboratory  data) are listed by  [CONTACT_655169].
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879410]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879411]

[COMPANY_001] / Incyte Corp. Confidential Page 68
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Table 6-[ADDRESS_879412] a mendment 4 -Core study  period (from screening to Day  168)
CategoryReference 
to 
assessment 
typesScreening Day 1 to Da y 28 Day 29 to
Day 56Day 57 to Da y 168For EOT and FU visits-Refer to Table 6-2 and 6-3(± 1-day  
window)(+ 3 
days)(± 2-
days)(± 3-day s window)
Visit no. 1 2 3 4 5 6 7 8 9 10
Study  Day -21 to -7 1 15 29 43 57 85 113 141 168
Obtain Informed 
ConsentD6.1.1 / 10.3. Before 
screening
Demography D6.1.1.3 . X
Inclusion/exclusion 
criteriaD4.1/ 4.2.X
Discuss pregnancy 
prevention methodsS5.1.11 .X
Prior antineoplastic 
therapyD6.1.1.3 .X
Relevant medical 
history/current medical 
conditionsD6.1.1.3 .
X
Measurement of spleen 
by [CONTACT_655170]6.2.1 / 
[IP_ADDRESS] .X X X X X X X X X X
Vital signs D6.2.2.2 . X X X X X X X X X X
Height D6.2.2.3 . X
Weight D6.2.2.3 . X X X X X X X X
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879413]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879414]

[COMPANY_001] / Incyte Corp. Confidential Page 69
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
CategoryReference 
to 
assessment 
typesScreening Day 1 to Da y 28 Day 29 to
Day 56Day 57 to Da y 168For EOT and 
FU visits-Refer 
to Table 6-2 
and 6-3
(± 1-day  
window)(+ 3 
days)(± 2-
days)(± 3-day s window)
Visit no. 1 2 3 4 5 6 7 8 9 10
Study  Day -21 to -7 1 15 29 43 57 85 113 141 168
Complete physical 
examinationD6.2.2.1 .X X X X X X X X
Short physical 
examinationD6.2.2.1 .X X
ECOG performance 
statusD6.2.2.4 .X X X X X X X X
ECG D6.[IP_ADDRESS] . X X X X X
Laboratory Assessments
Serum chemistry tests D6.[IP_ADDRESS] / 
Appendix 12X X X X X X X X X
Hematology D6.[IP_ADDRESS] / 
Appendix 12X X X X X X X X X X
Coagulation test D6.[IP_ADDRESS] / 
Appendix 12X X X X X X
Serum Pregnancy Test D [IP_ADDRESS].[ADDRESS_879415] D6.[IP_ADDRESS] . X X X X X X
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879416]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879417]

[COMPANY_001] / Incyte Corp. Confidential Page 70
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
CategoryReference 
to 
assessment 
typesScreening Day 1 to Da y 28 Day 29 to
Day 56Day 57 to Da y 168For EOT and 
FU visits-Refer 
to Table 6-2 
and 6-3
(± 1-day  
window)(+ 3 
days)(± 2-
days)(± 3-day s window)
Visit no. 1 2 3 4 5 6 7 8 9 10
Study  Day -21 to -7 1 15 29 43 57 85 113 141 168
Blood sampling for PK 
(not applicable for 
patients in safety 
expansion phase )D6.2.3 .
X X X X
Prior/concomitant 
medicationsD6.1.1.3 / 
5.1.8 , 5.1.9 , 
5.1.10 , 
5.1.11 .X X X X X X X X X X
Adverse events D7.1. X X X X X X X X X X
INC424 morning dose at 
siteD6.2.3.2 .X X
Drug accountability 
assessment (Return of 
INC424 review of paper 
compliance diary)D5.2.4.2 .
X X X X X X X X
Dispense INC424 D5.2.3 . X X X X X X X X X
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879418]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879419]

[COMPANY_001] / Incyte Corp. Confidential Page 71
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Table 6-[ADDRESS_879420] amendment 4 -Extension study  period and End of Treatment
CategoryReference to 
assessment 
typesExtension period
(± 7-day s window)Extension 
visits ([LOCATION_006] 
patients 
only)End of 
treatment
(Core or 
Extension)
/ [[LOCATION_006] only : 
Week 156
andEOT]End of 
follow -up
(± 3-day s 
window)
(Core or 
Extension)
Visit no. 11 12 13 14 15 16, 17, etc
Study  WeekWeek 36
(Day 252)Week 48
(Day 336)Week 60
(Day 420)Week 72
(Day 504)Week 84
(Day 588)Week 96+ 
q12 weeks 
thru Week 
144Week 168 
+ q12 
weeks thru 
LPFV + 
[ADDRESS_879421] / 
Week [ADDRESS_879422] 
dose
Measurement of spleen by 
[CONTACT_655170]6.2.1 / [IP_ADDRESS] .X X X X X X X X
Vital signs D6.2.2.2 . X X X X X X X X
Weight D6.2.2.3 . X X X X X X X X
Complete physical 
examinationD6.2.2.1 .X
Short physical examination D6.2.2.1 . X X X X X X X
ECOG performance status D6.2.2.4 . X X X X X X X X
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879423]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879424]

[COMPANY_001] / Incyte Corp. Confidential Page 72
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
CategoryReference to 
assessment 
typesExtension period
(± 7-day s window)Extension 
visits ([LOCATION_006] 
patients 
only)End of 
treatment
(Core or 
Extension)
/ [[LOCATION_006] only : 
Week 156
andEOT]End of 
follow -up
(± 3-day s 
window)
(Core or 
Extension)
Visit no. 11 12 13 14 15 16, 17, etc
Study  WeekWeek 36
(Day 252)Week 48
(Day 336)Week 60
(Day 420)Week 72
(Day 504)Week 84
(Day 588)Week 96+ 
q12 weeks 
thru Week 
144Week 168 
+ q12 
weeks thru 
LPFV + 
[ADDRESS_879425] / 
Week [ADDRESS_879426] 
dose
ECGD6.[IP_ADDRESS] . X
If before 
Day 168
Prior/concomitant 
medicationsD6.1.1.3 / 5.1.8 , 
5.1.9 , 5.1.10 , 
5.1.11 .X X X X X X X X X
Adverse events D7.1. X X X X X X X X X
Drug accountability 
assessment (Return of 
INC424 review of paper 
compliance diary)D5.2.4.2 . X X X X X X X X
Dispense INC424 D5.2.3 . X X X X X X X
Antineoplastic therapi[INVESTIGATOR_655135]424D6.1.5 . X
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879427]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879428]

[COMPANY_001] / Incyte Corp. Confidential Page 73
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Table 6-[ADDRESS_879429] amendment 4 –Extension study period
Category
Reference to assessment typesExtension period
(± 7-day s window)Extension visits ([LOCATION_006] 
patients only )End of Treatment
(Core or 
Extension) / [[LOCATION_006] 
only: Week 156
and EOT ]Endpoint 
follow up (+ 3 -
days window)
(Core or 
Extension)
Visit No. Clinic Visits
Study  WeekWeeks 36,48, 60, 72, 84, 96, 108, 
120, 132 & 144Week 168 + q12 
weeksLast
Week [ADDRESS_879430] dose
Serum chemistry 
testsD6.[IP_ADDRESS] . / ALT, AST, Alkaline 
phosphatase, Total and Direct 
Bilirubin, Albumin, Lactate 
dehydrogenase, Creatinine, BUN, 
Sodium, Potassium, Glucose, 
Calcium, Uric acid ( Appendix 12 )XNo lab  visits  required after  Week 156
XX
if occurs in Core 
Phase
HematologyD6.[IP_ADDRESS] . / Complete Blood Count 
(CBC) Differential, including 
reporting of % blasts, Platelets 
(Appendix 12 )X X X
Urine Pregnancy 
testD6.[IP_ADDRESS] .X X
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879431]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879432]

[COMPANY_001] / Incyte Corp. Confidential Page 74
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
6.1.[ADDRESS_879433] result(s), apart from an ECG finding that does not satisfy 
the eligibility  criteria may have the 
test(s) repeated once. These tests may be repeated as soon 
as the Investigator believes that the retest result is likely  to be within the acceptable range to 
satisfy  the entrance criteria, but should be completed within [ADDRESS_879434](s) cannot be performed within [ADDRESS_879435](s) do 
not meet the entrance criteria (apar t from platelet count, see also Section [IP_ADDRESS]) or the 
patient’s medical condition has changed significantly  during the screening period so that 
inclusion/exclusion criteria are no longer met, the patient is considered a Screen failure, and 
must be discontinued from the study . If the patient and Investi
gator choose to re-screen the 
patient, the patient must sign a new ICF, a new patient ID number will be assigned by [CONTACT_3786] , and all required Screening activities must be performed when the patient is re-
screened for participation in the study . Anindividual patient may only re-Screen once per 
stratum for the study . Once the number of patients screened and enrolled in the respective 
dose cohort and stratum is likely  to assure target enrollment, the Sponsors may, at its 
discretion, close the dose cohort and stratum study  to further screening. In this case, patients 
who screen fail will not be permitted to re -Screen.
[IP_ADDRESS] Eligibility  screening
Patients must meet all inclusion and exclusion criteria at Screening or at Day [ADDRESS_879436] study  treatment within 7 
days.Therefore any of the 4 platelet count values (at screening, at screening re-test, at the 
planned day of first study  treatment or at its re-test) may qualify  the patient in the study . The 
day at which the treatment will eventually  start will be defined as the Study  Day 1. If the 
platelet count value is not within the permitted range neither at Screening nor at Study  Day [ADDRESS_879437] the clinical databa se for accuracy . Only  when 
eligibility  has been confirmed will the patient be assigned to a treatment stratum and dose 
level. Additionally , investigative site staff will enter patient information into the eCRF, and 
automated queries will be generated for immediate resolution should patient eligibility  be in 
question based on the patient information entered.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879438]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879439]

[COMPANY_001] / Incyte Corp. Confidential Page 76
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
141, and 168).    Thereafter, in the extension study  period, the on-treatment study  visits will 
beevery  12 weeks from Day 168(on Days 252, 336, 420, 504, 588, etc.) through Week 144 
and an EOT visit scheduled for Week 156. There will not be any required laboratory - only 
visits.
[The above paragraph will read as follows for the [LOCATION_008] onl y: 
For [LOCATION_006] patients only, with the implementation of Amendment 4, during the core treatment 
period, from screening until Day 168, on-treatment study  visits are scheduled every  [ADDRESS_879440] 8 weeks (Study  Days 1, 15, 29, and 43), then every  4 weeks until Day 168 (Study  
Days 57, 85, 113, 141, and 168).  Thereafter, in the extension study  period, the on-treatment 
study  visits will be every 12 weeks from Day 168 (on Days 252, 336, 420, 
504, 588, etc.) 
through Week 156. After Week 156, patients will return to the site every  12 weeks until L PFV 
plus 156 weeks, when the EOT visit will be performed.  There will not be any required 
laboratory -only visits.]
For all patients, core treatment period visit windows are as follows: Day 15 has a ± 1-day 
window, Day 29 has a +3 day window, Day 43 ha
sa ± 2-days window, Study  Days 57, 85, 
113, [ADDRESS_879441] a ± [ADDRESS_879442] a ± [ADDRESS_879443] 8 hours,
with exception formorning medications for any other medical indication e.g. hypertension 
should be taken w ith a small amount of water. However Study  Visits should still be conducted 
if the patient does not adhere to fasting requirements and this will not be considered a protocol 
violation. If, at any time during the study , a patient experiences unexpected signs or 
symptoms, additional safet y evaluations should be conducted at a regular Study Visit or 
unscheduled visit.
[For [LOCATION_008] patients only :
Since [LOCATION_006] patients can continue beyond the 3 year treatment period, study visits will continue 
to occur every 12 weeks after Week 156. However, for these subsequent visits, ONL Y the 
following summary  eCRFs should be completed: Adverse events, Concomitant Medications, 
Dose Administration Records, Transfusions, and Non-drug Therapi[INVESTIGATOR_73910].
Laboratory  ass
essments, vital signs, and phy sical examination findings will not be captured in 
the eCRF (unless constituting an adverse event), but will be recorded in the source documents 
at the study  center .
At end of treatment andat study  discontinuation, all [LOCATION_006] patients, including those with visits 
after Week 156, are required to complete the end of treatment and study  evaluation 
completion assessments .The corresponding eCRFs will need to be completed .]
6.1.4 Discontinuation of Study Treatment / Study
Patients may voluntaril y discontinue from study  treatment and from the study  for any reason 
at any time. If a patient decides to discontinue from the study  treatment
/ study  , the 
investigator should make a reasonable effort (e.g., telephone, e-mail, letter ) to understand the 
primary  reason for this decision (or as per local regulation) and record this information in the 
patient’s chart and on the appropriate eCRF pages. Patients may be considered withdrawn if 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879444]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879445]

[COMPANY_001] / Incyte Corp. Confidential Page 77
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
they state an intention to withdraw, fail to return for visits, or become lost to follow -up for 
any other reason.
The investigator should discontinue study  treatment and discontinuation from the study  for a 
given patient if he/she believes that continuation would be detrimental to the patient’s well-
being.
Study  treatment must be discontinued and study  participation ended under the following 
circumstances:
Emergence of the following treatment related adverse events or lab abnormalities (see 
Section [IP_ADDRESS] and Table 5 -4:
oGrade 3 or 
4 hemorrhagic event of any  kind
oSecond epi[INVESTIGATOR_254335] >3 febrile neutropenia (ANC < 1.0 x 109/L, with a single 
temperature of ≥ 38.3 °C or a sustained temperature of ≥ 38 °C for more than one 
hour)
oGrade 3 renal toxicity  for ≥ [ADDRESS_879446] bilirubin > 0.5 mg/dL
oGrade 4 non -hematologic toxicity
oGrade 4 serum creatinine related to treatment from Day  1 to Day  28
oSecond epi[INVESTIGATOR_1865] o f grade 3 or 4 serum creatinine from Study  Day  29
oGrade 4 other adverse event
oPlatelet counts reduce < 25 x 109/L while taking INC424 at 5mg qd
Pregnancy
The following deviations from the prescribed dose regimen:
oInterruption of stud y treatment for > 28 da ys regardless of reason
oIf after 2 dose reductions and after the treatment has resumed at the lower dose, the 
same toxicity  recurs with the same or worse severity  (except for thrombocytopenia, 
anemia, and neutropenia)
oIf a patient cannot tolerate dose leve l (-1)(5 mg qd) , which is the lowest acceptable 
dosing level for this study.
There is disease progression (see Section 6.2.1). As an exception, if, despi[INVESTIGATOR_655136]  > 40% incre ase in spleen size and not by  [CONTACT_655171], the Investigator believes that it is in the patient’s best interest to continue 
therap y with INC424 due to symptomatic improvement, the patient may  continue therap y, 
only after consultation with the Sp
onsors.
Use of prohibited treatments (refer to Appendix 1) as determined b y [COMPANY_001]
Patient undergoes splenic irradiation
Patient undergoes splenectomy . As an exception, patients who participate in the safet y 
expansion phase of the study  are allowed to continue in the study , provided that they  have 
fully  recovered from the surgery  and are discharged from the hospi[INVESTIGATOR_307].
Death
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879447]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879448]

[COMPANY_001] / Incyte Corp. Confidential Page 78
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Any other protocol deviation that results in a significant risk to the patient’s safet y
Patient has completed 3 y ears of treatment a nd another treatment option is available
Patient is non -complaint with the protocol 
Study  is terminated by  [CONTACT_655172] a week for [ADDRESS_879449] dose of INC424.
Patients who discontinue study  treatment and study  participation should return for the 
assessments indicated in Table 6-1, Table 6-2, and Table 6-3for safet y reasons . If they fail to 
return for these assessments for unknown reasons, every  effort (e.g. telephone, email, letter) 
should be made to contact [CONTACT_15026] 6.1.6 . 
[IP_ADDRESS] Replacement policy
Patients withdrawn from the study  will not be replaced.
However , if, from Study  Day 1 through Study Day 28, a pati ent misses > 6 consecutive doses
of treatment or > 20% of the planned study  drug doses , the patient can continue in the study  
without being evaluable for DLTs. Consequentl y, another patient has to be enrolled into the 
same dose level and stratum in order to reach the required number of patients in the cohort .
6.1.[ADDRESS_879450] to follow -up
For patients whose status is unclear because they  fail to appear for study  visits without stating 
an intention to withdraw consent, the investigator should show “due diligence” by [CONTACT_15027], family , or family  physician as agreed in the informed consent and by  [CONTACT_655173] (e.g. dates of telephone calls, 
registered letters, etc.).  A  p atient should not be considered lost to follow -
up until due 
diligence has been completed.  Patients lost to follow up should be recorded as such on the 
appropriate Disposition eCRF.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879451]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879452]

[COMPANY_001] / Incyte Corp. Confidential Page 79
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
6.1.[ADDRESS_879453] alread y been collected may be 
retained and anal yzed at a later date (or as required by  [CONTACT_427]).
If a patient withdraws consent, the investigator should make a reasonable effort (e.g. 
telephone, e
-mail, letter) to understand the primary  reason for this decision (or as per local 
regulation) and record this information.
Study  treatme nt must be discontinued and no further assessments conducted.
Further attempts to contact [CONTACT_632761].
6.[ADDRESS_879454] 
of measurement of the spleen length by [CONTACT_655174] 24 (Study  Day 
168) in comparison to the Study  Day  [ADDRESS_879455] a ≥ 50% reduction in 
spleen size by [CONTACT_655175] 1  w ill be 
considered as responders, otherwise they will be considered non-responders. Spleen length 
measurements will continue to be measured after Week 24 to evaluate spleen length and 
percent change from baseline over time. In addition spleen lengths measurements will be 
conducted at every  study visit in order to exclude disease progression, which is a criterion for 
patient withdrawal (see Table 6-1, Table 6-2, Table 6-3 and Section [IP_ADDRESS]). Disease 
progression will be documented by > 
40% increase in spleen size by [CONTACT_655176] 1 orby [CONTACT_577842]’s expert judgment orby [CONTACT_655177] (as evidenced by [CONTACT_546723] 20%, or peripheral blast counts of at least 20% lasting at least 2 
weeks).
The edge of the spleen shall be determined by [CONTACT_23302] ,and measured in centimeters, from 
the costal margin to the point of greatest splenic protrusion. Investigator s will be provided 
with a soft centimeter ruler so that palpable spleen length is measured 
in centimeters and not 
in finger breadths. No imaging studies of an y kind will be required for efficacy  assessments.
6.2.2 Safety  and tolerability
Safet y will be monitored by  [CONTACT_655178]. 
For details on AE collection and reporting, refer to Section 8.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879456]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879457]

[COMPANY_001] / Incyte Corp. Confidential Page 80
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
[IP_ADDRESS] Physical examination, weight, height
A complete physical examination will be performed ,as noted in Table 6-1, Table 6-2, and 
Table 6-3. It will include the examination of general appearance and vital signs (blood 
pressure [BP] , respi[INVESTIGATOR_697], temperature and pulse) , skin, head, eyes, ears, nose, neck 
(including thyroid), 
throat, lungs, heart, abdomen (liver, spleen) , back, lymph nodes, edema 
and extremities, vascular and neurological. In addition, the examination will include body 
systems as indicated by [CONTACT_44239], AEs, prior physical examination, past medical 
history  or other findings as determined by [CONTACT_737]. Measurement of spleen size, 
assessed by [CONTACT_577848] a soft ruler, from the costal margin 
to the point of greatest splenic protrusion, will be performed at every  visit. The above 
described detailed phy sical examina tion will be conducted during the Screening Visit, the first 
day of every  treatment cycle, the End of Treatment visit, and the follow up visit (Table 6-1, 
Table 6
-2, and Table 6-3). During the intermediate visits of the cycles 1 and 2, only short 
physical examinations will be performed, which will include general appearance and vital 
signs (blood pressure [BP] , respi[INVESTIGATOR_2842], temperature and pulse) , skin, lungs, heart, 
abdomen 
(liver, spleen), edema and extremities, body  systems as indicated by [CONTACT_655179], AEs, and measurement of spleen size ( Table 6-1, Table 6 -2, and Table 6 -3).
Significant findings that were present prior to the signin g of informed consent must be 
included in the Relevant Medical History /Current Medical Conditions page on the patient’s
eCRF. Significant new findings that begin or worsen after informed consent is signed must be 
recorded on the Adverse Event page of the patient ’s eCRF.
[IP_ADDRESS] Vital signs
Vital signs (blood pressure, pulse , respi[INVESTIGATOR_381064]) will be collected 
according to the Visit Schedule outlined in Table 6-1, Table 6-2, and Table 6-3. Vital signs 
will be taken with the 
patient in the sitting position after [ADDRESS_879458]. Body  temperature 
may be measured orally  or via ear.
[IP_ADDRESS] Heigh t and weight
Height in centimeters (cm) will be measured only at screening. Body weight in kilograms (to 
the nearest 0.1 kilogram [kg] in indoor clothing, but without shoes) will be measured during 
the Screening Visit, the first day of every  treatment cycle, the End of Treatment visit, and the 
follow up visit ( Table 6-1, Table 6-2, and Table 6 -3).
[IP_ADDRESS] Performance status
The performance status will be assessed according to the 
ECOG performance status scale as 
noted in Table 6-1, Table 6-2, and Table 6-3. The ECOG performance status is graded on a 
six point scale (range 0 to 5): 0=As ymptomatic (Fully  active, able to carry  on all pre-disease 
activities without restriction); 1=Symptomatic but comple tely ambulatory  (Restricted in 
physically  strenuous activity  but ambulatory  and able to carry
 out work of a light or sedentar y 
nature. For example, light housework, office work); 2=Sy mptomatic, < 50% in bed during the 
day (Ambulatory  and capable of all self care but unable to carry  out any work activities. Up 
and about more than 50% of waking hours); 3=Symptomatic, > 50% in bed, but not bedbound 
(Capable of only limited self-care, confined to bed or chair 50% or more of waking hours); 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879459]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879460]

[COMPANY_001] / Incyte Corp. Confidential Page 82
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
[IP_ADDRESS] Cardiac assessments
[IP_ADDRESS].1 Electrocardiogram (ECG)
A standard 12 lead ECG will be performed:
at screening
at Study  Day s 1, 29, 85, 16 8
at the End of Treatment visit if before Day [ADDRESS_879461] be recorded on the Adverse E vents page.
6.2.3 Pharmacokinetics
[IP_ADDRESS] Rationale for incorporating pharmacokinetic evaluations
Pharmacokinetic evaluations incorporated in this study will aim to:
1. C ompare the low -PLT MF population with the MF population enrolled in the phase I/ II 
[INCB [ZIP_CODE] -251] and the phase III [INCB [ZIP_CODE]-351] and [INCB [ZIP_CODE] -352] studies .
2. C ompare safety  and efficacy  profiles (sensitivity  to exposure) of this population to 
[INCB18424-251] , [INCB [ZIP_CODE] -351] , and [INCB [ZIP_CODE] - 352] study  populations in order 
to make dose recommendations for low -platelet MF if there is a clinicall y significant 
difference .
[IP_ADDRESS] Pharmacokinetic blood sample collection and handling
Eight blood samples for pharmacokinetic (PK) analy ses will be collected from patients over 4 
visits in accordance with the study  schedule.
Three PK samples will be taken at Study  Day 1 visit after completion of screening visit and 
administration of study  drug (Sample #1: [ADDRESS_879462] dose, Sample #2: [ADDRESS_879463] dose, and Sample #3: 4-[ADDRESS_879464] dose) . Patients will withhold the morning 
dose of INC424 on the Study  Day 
15visit. At the study  clinic, Sample #[ADDRESS_879465] 
prior to administration of the morning dose of study  drug, followed by [CONTACT_655180] #[ADDRESS_879466] dose and Sample #[ADDRESS_879467] dose. Sample #7 will be 
randomly  drawn at Study  Day 29visit, and Sample #8 will be randoml y drawn at Study  Day 
57visit (see Table 6-4 ).
The exact date and time of the PK blood draws will be recorded along with the dates, times, 
and mg doses of the last dose of INC424 that preceded the blood draw and any  other doses on 
the day  of the blood draw that precede the blood draw. The actual dose regimen from the prior 
day should also be recorded. Patients that arrive for the Study  Day 15visit having alread y 
taken their morning dose should be reminded to come back within the next [ADDRESS_879468] dose 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879469]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879470]

[COMPANY_001] / Incyte Corp. Confidential Page 83
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
should be reminded to come back within the next [ADDRESS_879471]-
study 
drug 
administr
ationTrough: 
0.5 hour 
prior to 
study 
drug 
administr
ation*0.25-0.[ADDRESS_879472]-
study 
drug
Sample 
No1 2 3 4 5 6 7 8
Plasma 
sampleX** X** X** X** X** X** X X
* Sample collected [ADDRESS_879473] -study drug for b.i.d. dose regimen. Study drug administered approximately 30 
min after sample collection.
**Plasma samples at these time points are collected on the same day on the sin gle visit specified.
[IP_ADDRESS] Analytical method
The plasma samples will be analy zed for INC424 by a validated LC/MS/MS assay , carried 
out by[CONTACT_1034] s’ designee. Plasma concentrations of INC424 will bedetermined 
following a liquid/liquid extraction procedure using methy l-t butyl ether (MTBE) with 13C4-
INC424 (INCB028452) as the internal standard. Chromatograph y will beperformed with a 
Phenomenex Synergi 4µ Polar -RP 80A (30 x 2 mm) column under isocratic conditions and a 
mobile phase consisting of 55% acetonitrile and 45% 2mM ammonium acetate aqueous 
solution. LC/MS/MS analy sis will beperformed using a positive Turbo IonSpray®interface 
on a Sciex API-3000 and multiple reaction monitoring (MRM). Using 50 µL plasma, this 
assay  produce slinear results over a plasma concentration range of 1.0-1000 nM for INC424 , 
corresponding to the lower and upper quantitative limits, res pectively .
6.2.4 Other assessments
[IP_ADDRESS] Pharmacody namics
[IP_ADDRESS].1 Rationale for incorporating pharmacodynamic evaluations
Pharmacody namic evaluations incorporated in this study  will aim to:
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879474]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879475]

[COMPANY_001] / Incyte Corp. Confidential Page 86
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Adverse Events will be assessed according to the Common Terminology Criteria for Adverse 
Events (CTCAE) version 4.03. If CTCAE grading does not exist for an Adverse Event, the 
severit y of mild, moderate, severe, and life-threatening, orgrades 1-4, will be used. CTCAE 
grade 5 (death) will not be used in this study ; rather, information about deaths will be 
collected through a Death form. The occurrence of Adverse Events should be sought by [CONTACT_105]-
directive questioning of the patient during the screening process after signing informed 
consent and at each visit during the study . Adverse Events also may  be detected when they  are 
volunteered by [CONTACT_655181], or 
through physical 
examination, laboratory  test, or other assessments. As far as possible, each Adverse Event 
should be evaluated to determine:
The severity  grade (CTCAE grade 1 -4)
Causality  to the Adverse Event (reasonable possibility  that the AE is related to the study  
drug). Since this is an open -label stud y,the relationship to study  drug is only  assessed for 
INC424. For stud y investigative site s in EU: if the AE is serious, then the causality  to 
INC424 needs to be assessed to comply  with requirements according to the EU Clinical 
Studies Directive.
Start and end dates, unless unresolved at the follow- up visit
Action taken with respect to study drug (none, dose adjusted, temporarily  interrupted, 
permanentl y discontinued, unknown, not applicable)
Outcome (not recovered/not resolved, recovered/resolved, recoverin g/resolving, 
recovered/resolved with sequelae, fatal, unknown)
Whether it is serious, as per SAE definition provided in Section 7.2.
Unlike routine safety assessments, SAEs are monitored continuously and have special 
reporting requirements, see Section 7.2
.
All Adverse Events should be treated appropriately . Treatment may include one or more of 
the following: no action taken (i.e. further observation only); study  drug dosage 
adjusted/temporaril y interrupted; study  drug permanently  discontinued due to this adverse 
event; concomitant medication given; non-drug therapy  given; patient hospi[INVESTIGATOR_057]/patient’s 
hospi[INVESTIGATOR_18533]. The action taken to treat the adverse event should be recorded on 
the Adverse Event eCRF.
Once an Adverse Event is detected, it shou ld be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequentl y, if 
necessary ) of any changes in severit y, the suspected relationship to the study  drug, the 
interventions required to treat it, and the outcome.
Disease progression should not be regarded or reported as an Adverse Event itself unless 
associated with a separate Adverse Event.
Whenever possible, a diagnosis should be reported instead of underl ying signs and s ymptoms.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879476]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879477]

[COMPANY_001] / Incyte Corp. Confidential Page 87
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
7.1.[ADDRESS_879478] abnormalities
[IP_ADDRESS] Definitions and reporting
Abnormal laboratory  values or test results that constitute adverse events or underly ing 
conditions should not be reported separatel y in addition to the respective adverse events or 
underl ying diagnosis.
Additionally , laboratory abnormalities that are considered clinicall y significant due to 
induction of clinical signs or symptoms, or requiring concomitant therap y (e.g. any 
hematologic abnormalit y that requires transfusion or cytokine treatment) or changes in study  
medication, should be recorded on the Adverse Events eCRF. Whenever possible, a diagnosis, 
rather than a symptom should be provided (e.g. anemia instead of low hemoglobin). 
Laboratory  abnormalities that meet the criteria for Adverse Events should be followed until 
they have returned to normal or an adequate explanation of the abnormalit y is found.
Laboratory  abnormalities, that do not meet the criteria of clinical significance, as judged by 
[CONTACT_737] , should not be reported as Adverse Events . A grade 3 or 4 event (severe) as 
per CTCAE does not automatically  indicate a SAE unless it meets the definition of serious as 
defined below and/or as per Investigator ’s discretion. Dose modifications described in the 
Table 5-4for lab abnormalit iesshould not contribute to designation of a lab parameter 
abnormality  as a SAE .
7.2 Serious adverse e vents
7.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life
-threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may  
require medical or surgical intervention to prevent one of the o utcomes listed above
Requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]:
Routine treatment or monitoring of MF, not associated with any  deterioration in 
condition
Elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
Social reasons and respi[INVESTIGATOR_064]’s 
general condition
Any SAEs that are expected due to MF , including if the SAE is a primary  outcome 
measure, and whether there has been a cle ar agreement with regulators not to consider 
these as SAEs, provided the information is collected elsewhere
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879479]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879480]

[COMPANY_001] / Incyte Corp. Confidential Page 88
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
7.2.[ADDRESS_879481] the relationship of each SAE to the study  drug, 
complete the SAE Report Form in English, and send the completed, signed form by  [CONTACT_87109] 
24 hours to the Sponsor s’ Integrated Medical Safety  (IMS) department.
The telephone and telefax number of the contact [CONTACT_655182] y (IMS), specific to the site, are listed in the investigator folder provided to each 
site. The original copy  of the SAE Report Form and the fax confirmation sheet must be kept 
with the case report form documentation at the study site.
Follow-up information is sent to the same person to whom the original SAE Report Form was 
sent, using a new SAE Report Form stating that this is a follow -up to the previously  reported 
SAE and giving the date of the original report. Each re-occurrence, complica tion, or 
progression of the original event should be reported as a follow -up to that event regardless of 
when it occurs. The follow -up information should describe whether the event has resolved or 
continues, if and how it was treated and whether the patien t continued or withdrew from study  
participation.
If the SAE is not previously  documented in the Investigator’s Brochure (new occurrence) and 
is thought to be related to the Sponsor s’study drug, a Sponsor s’ associate may urgentl y 
require further informati on from the investigator for Health Authorit y reporting. Sponsors
may need to issue an I nvestigator Notification (IN), to inform all investigators involved in any 
study  with the same drug that this SAE has been reported. Suspected Unexpected Serious 
Advers e Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and 
relevant ethics committees in accordance with Directive 2001/20/EC or as per national 
regulatory  requirements in participating countries.
7.2.[ADDRESS_879482] be reported to 
the Sponsors within 24 hours of learning of its occurrence. The pregnancy  should be follo wed 
up to determine outcome, including spontaneous or voluntary  termination, details of the birth, 
and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or 
newborn complications.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879483]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879484]

[COMPANY_001] / Incyte Corp. Confidential Page 89
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Pregnancy  should be recorded on a Clinical Study  Pregnancy  Form and reported by [CONTACT_655183] . Pregnancy  follow -up should be recorded on the same form and 
should include an assessment of the possible relationship to the Sponsor s’ study  drug of any 
pregnancy  outcome. Any SAE experienced during pregnancy  must be reported on the SAE 
Report Form.
7.4 Warnings and precautions
No evidence available at the time of the approval of this study  protocol indicated that special 
warnings or precautions were appropriate, other than those noted in the provided Investigator
Brochure. Additional safety  information collected between IB updates will be communicated 
in the form of Investigator Notifications (IN). This information will be included in the patient 
informed consent and should be discussed with the patient during the study as needed.
7.5 Data Monitoring Committee
Not applicable.
7.6 Steering Committee
Not applicable.
8 Data revie w andmanagement
8.1 Data confidentiality
Information about study  patients will be kept confidential and managed under the appli cable 
laws and regulations. Those regulations require a signed patient authorization informing the 
patient of the following:
What protected health information (PHI) will be collected from patients in this study
Who will have access to that information and why
Who will use or disclose that information
The rights of a research patient to revoke their auth orization for use of their PHI .
In the event that a patient revokes authorization to collect or use PHI, the Investigator , by 
[CONTACT_5151], retains the ability  to use all information collected prior to the revocation of patient 
authorization. For patients that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect at least vit al status (i.e. that the patient is alive) 
at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 
information. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who 
have completed prerequisite training.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879485]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879486]

[COMPANY_001] / Incyte Corp. Confidential Page 90
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
8.2 Site monitoring
Before study  initiation, at a site initiation visit or at an Investigator ’s meeting, Sponsor s’
personnel (or designated CRO) will review the protocol and eCRFs with the Investigator s and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the eCRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study  drug is 
being stored, dispensed, and accounted for according to specifications. Key study personnel 
must be available to assist the field monitor during these visits.
The Investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on eCRFs must be traceable to source documents in the 
patient's file. The Investigato rmust also keep the original informed consent form signed by 
[CONTACT_102] (a signed copy  is given to the patient).
The Investigator must give the monitor access to all relevant source documents, including 
electronic documents if that is the source, to confirm their consistency  with the eCRF entries. 
Sponsors monitoring standards require full verification for the presence of informed consent, 
adherence to the inclusion/exclusion criteria and documentation of SAEs. Additional checks 
of the consistency  of the source data with the eCRFs are performed according to the study -
specific monitoring plan.
8.3 Data collection
The designated investigator staff will enter the data required by [CONTACT_230787] (eCRF) using fully  validated software that conforms to [ADDRESS_879487] been trained.
The Principal Investigator [INVESTIGATOR_111784], accurate, and that entry  is performed in a timely  manner.
Automatic validation programs check for data discrepancies in the eCRFs and, by [CONTACT_655184], allow the data to be confirmed or corrected in a timely  manner 
before it is reviewed by  [CONTACT_655185] (DM) group. Before transfer to the Sponsors (or 
designated CRO) via a secure network the investigator must certify  that the data entered into 
the Electronic Case Report Forms are complete and accurate. After database lock, the 
investigator will receive a CD-ROM or paper copi[INVESTIGATOR_655137].
8.4 Database management and quality  control
Data will be ent ered into the study  database b y the designated investigator site staff .
Following data entry  into t he eCRFs, Sponsors personnel (or designated CRO) will review the 
data entered by [CONTACT_5375] . Electronic data queries 
stating the nature of the problem and requesting clarification will be created for all other 
discrepancies and missing values and sent to the investigati vesite via the EDC system. 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879488]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879489]

[COMPANY_001] / Incyte Corp. Confidential Page 92
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
The data will be summarized with respect to demographic and baseline characteristics, 
occurrence of dose -limiting toxicities (DLTs), efficacy  observations and measurements, safet y 
observations and measurements, an d pharmacokinetic/pharmacody namic measurements.
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, median, 25thand 75thpercentiles, minimum, and maximum will be 
presented.
All data will be listed unless otherwise specified.
9.1 Analysis sets
In general, data summaries will be presented by [CONTACT_655186]. Dose 
levels may be combined for summary  purposes based on the observed outcomes. For 
example, it may be prudent to summarize according to starting dose received as: lower than 
MSSD, MSSD, and higher than MSSD. DLT outcomes will be summarized separatel y by 
[CONTACT_655187]. Additional key safety information, such as incidence of hematologic 
adverse events and labs
, may be summarized separatel y by [CONTACT_64264].
9.1.1 Full A nalysis Set
The Full Anal ysis Set (FAS) comprises all patients who received at least one dose of study  
medication.
9.1.[ADDRESS_879490] one dose of study  medication. 
Patients will be analy zed according to the study  treatment (regimen) they  actually  received.
A precise definition of “actually received” will be added in the RAP.
9.1.3 Dose -determining Set
The Dose -determining Set (DDS) consists of all patients from the safety set who either (i) 
meet the minimum exposure criterion and have sufficient safety  evaluations as defined below, 
or (ii) discontinue due to DLT. The patients in the DDS enrolled in the dose-finding part of 
the study  will be the patients used for determinatio n of the MSSD.
A patient is considered to have met the minimum exposure criterion and to have had sufficient 
safet y evaluations if they have not missed >20% of the planned doses and no more than [ADDRESS_879491] completed all required safet y evaluations 
through Stud y Da y 28.
9.1.4 Pharmacokinetic analy sis set
The Pharmacokinetic Analy sis Set (PAS) consists of all patients with at least one evaluable 
pre-dose plasma PK sample at any  visit. A pre -dose plasma PK sample is defined a s evaluable 
if it is received within 3 hours of the scheduled time (e.g., between 8-16 hours following the 
previous day  dosing).
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879492]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879493]

[COMPANY_001] / Incyte Corp. Confidential Page 93
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
9.2 Patient demographics/other baseline characteristics
Demographic and other baseline data will be summarized descriptively  by [CONTACT_655188]. Categorical data will be presented as frequencies and percentages. For continuous data, 
mean, standard deviation, median, 25thand 75thpercentiles, minimum, and maximum will be 
presented.
9.3 Treatments (study  drug, concomitant therapi[INVESTIGATOR_014], compliance)
The dose and duration of INC424 will be listed and summarized by [CONTACT_655189]. Data may be presented by [CONTACT_655190]. The daily dose will be summarized using descriptive statist ics by [CONTACT_655191].
Concomitant medications and significant non-drug therapi[INVESTIGATOR_655138] y set.
Compliance to the study protocol will be assessed by [CONTACT_655192]. These will be identified prior to database lock and will be listed and 
summarized. Compliance to study  drug,for the period from Study  Day 1 to end of treatment, 
will be summarized by [CONTACT_655193] < 83.3% vs. ≥83.3% and will be reported by [CONTACT_655194].
9.4 Primary  objective
The primary  objective of the study  is to determine the maximum safe starting dose (MSSD) of 
INC424 given orally, twice -
a-day, in a 28-day cycle to patients with myelofibrosis who have 
baseline platelet counts belonging to 1 of 2 strata: (1) [75 -
100x 109/ L) or (2) [50 - 75x 109
/ L).
The corresponding primary  analysis method is an adaptive Bay esian logistic regression model 
guided by [CONTACT_655161] (EWOC) ( Babb et al 1998). A prior distribution 
for the model parameters is derived based on 
experience with INC424 in adult patients in 
clinical study  [INCB [ZIP_CODE]-251] , which was the dose-finding study  in patients with 
myelofibrosis that preceded the pi[INVESTIGATOR_655131] [INC424A -351] and [INC424A -352]
(see Section 1.2.4 ). This prior distribution is then updated after each cohort of patients in each 
stratum with the DLT data from the current study . A detailed descriptio n of the used 
methodology  can be found in Section 9.4.2 and Appendix 13.
9.4.1 Variable
Estimation of the MSSD in the dose-escalation part of the study  will be based upon the 
estimation of the probability  of DLT for patients in the DDS. This probability  is estimated 
from the model described in Section 9.4.2 .
The definition of DLT is provided in Section [IP_ADDRESS] .
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879494]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879495]

[COMPANY_001] / Incyte Corp. Confidential Page 94
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
9.4.2 Statistical hy pothesis, model, and method of analy sis
Statistical model
The statistical model for MSSD estimation will be based on a 3-parameter Bayesian logistic 
regression model. Let π(d)be the probability of DLT 
at total daily dosed (in mg), and let d*
denote a reference dose of INC424. Then the 3 -parameter logistic model relating the log -odds 
for a DLT to the dose and stratum is of the form
logit(π (d)) = log(α) + β log(d/d*) + γI {pt is in stratum 2} ,
where logit(π (d))= log e((d)/(1-(d))), α, β > 0, and -∞ < γ < ∞. Doses are rescaled as d/d*, and 
as a consequence α is equal to the odds of the probability  of DL T at d*for a patient in stratum 
1. If a patient is from stratum 2, the indicator I{pt is in stratum 2}takes the value 1, otherwise it 
takes the value zero. Therefore, γ may be interpreted as the log-odds ratio for the probabilit y 
of DLT between patients from stratum 2 to patients from stratum 1.
Prior specifications
The derivation of the final prior for usage in this study  was a several step process which 
capi[INVESTIGATOR_655139] 117 patients treated in the [INCB [ZIP_CODE] -251] study  at 
1 of 4 b.i.d. schedules as described in this section. The general approach was as follows:
Step 1: A Bay esian logistic regression model was applied to the [INCB [ZIP_CODE] -251] data using 
dose and baseline platelet count (as a continuous variable) as covariates, which resulted in 
posterior estimates for the model parameters, and the effect of the baseline platele t count 
when treated as a continuous covariate.
Step 2: Using the model from Step 1, the estimated probabilities of DL Ts were determined for 
the patients in stratum 1 of the current study . Since the assumed mean baseline platelet count 
in stratum 1 is 87 x109/L(i.e., the midpoint of the range permitted in stratum 1), an 
extrapolation of the model relative to the [INCB [ZIP_CODE]-251] data was required. In addition, an 
adjustment to the variance estimates was required to account for “between trial 
heterogeneity ”. Note that in stratum 1, the indicator applied to γ is zero, so the only model 
parameters are log (α) and log (β).
Step 3: The adjusted posterior estimates, as described in Step 2 and which are labeled as 
“Predicted”, were assigned 90% relat ive weight for the final prior. The remaining 10% weight 
was allocated to an additional “Low toxicity ” prior that was developed to ensure the final 
prior could react reasonably  well to data earl y on that are inconsistent with the prior from Step 
2.
Step 4:A minimally  informative prior for γ was developed assuming a relatively  strong (i.e.
conservative) stratum [ADDRESS_879496].
The final prior for the current study , as well as the resulting DLT prior probability  estimates 
for each stratum, are provided in Table 9-1.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879497]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879498]

[COMPANY_001] / Incyte Corp. Confidential Page 95
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Table 9-1 Final prior for the current study
Prior distributions for the current study : Priors for log (α) and log (β)are normally  distributed
Means
log (α), log (β)Standard deviations
log (α), log (β)Correlation Weight
Predicted -1.010, -0.259 0.876, 0.918 -0.103 0.9
Low toxicity -1.447, -0.385 1.095, 1.412 -0.065 0.1
Covariate (γ) log(1.5) 0.354 N/A N/A
Prior probabilities of under -dosing, targeted, and over -dosing for any  DLT
Total daily  
dosePrior probabilities that P(any DLT) is in 
intervalMean Standard 
deviation2.5% 50% 97.5%
[0.0,0.16) [0.16,0.33) [0.33,1.00]
Stratum 1
10mg 0.624 0.255 0.121 0.155 0.143 0.001 0.113 0.529
15mg 0.523 0.309 0.168 0.189 0.151 0.006 0.151 0.570
20mg 0.426 0.353 0.221 0.222 0.156 0.018 0.187 0.605
25mg 0.334 0.386 0.281 0.255 0.160 0.036 0.223 0.637
30mg 0.249 0.395 0.355 0.289 0.165 0.053 0.261 0.670
Stratum 2
10mg 0.502 0.274 0.224 0.207 0.180 0.001 0.159 0.654
15mg 0.393 0.312 0.296 0.250 0.186 0.008 0.209 0.691
20mg 0.298 0.334 0.369 0.290 0.189 0.025 0.255 0.720
25mg 0.215 0.339 0.446 0.329 0.191 0.048 0.300 0.748
30mg 0.150 0.321 0.529 0.368 0.193 0.070 0.346 0.776
Note: bold values indicate doses not meeting the overdose criterion.
Further details describing the steps outlined above are provided below.
Step 1
Data from study  [INCB [ZIP_CODE]-251] were used to derive an informative bivariate normal prior 
for the model parameters (log(α), log(β)). A 3-parameter Bayesian logistic regression model 
of the following form was used:
logit(π i) = log(α h) + β hlog(d i/d*) + γ h(log(c i) –
c*),
where diis the total daily  dose and cithe baseline platelet count of the i-th subject, logit(π i) = 
log[π i/{1- πi}], d*= 30mg (total daily  dose) is the reference dose of INC424, c*= (log(c 1) + 
log(c 2) + …+ log(c N))/N is the arithmetic mean of the logarithm of the baseline platelet 
counts of the N subjects evaluated in the study , αh, βh> 0 and -< γh< . πidenotes the 
probability  of a DLT of the i-subject accounted for his/her baseline platelet count. Note also 
that subscript h was used to denote parameters which were used the fit the data from the study 
i.e. αh, βhand γh. This is done in order to distinguish them from the parameters α, β and γ 
which will be estimated in the current study .
To predict the expected DLT probability  πpredat dose d and a certain level of baseline platelet 
count c pred, the above model was used in the following way :
logit(π pred,d) = log(α h) + β hlog(d/d*) + γ h(log(c pred) – c*).
The exact procedure is then given as follows:
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879499]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879500]

[COMPANY_001] / Incyte Corp. Confidential Page 96
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
A non-informative prior for (log(α h), log(β h)) and for γ hwas derived in the following way :
The median DLT rate at the reference dose (30mg total daily  dose) and at c* was 
assumed 1/3, i.e. mean(log(α h)) = log(1/2)
A doubling in dose was assumed to double the odds of DLT, i.e. mean(log(β h)) = 0
The standard devi ations of the two parameters were set to 2, such that the bivariate 
normal distribution covers approximately  95% of the probability space
The correlation was set to 0, assuming independence of log(α h) and log(β h)
A non- informative prior for γ hwas assumed b y specify ing a normal prior distribution 
with mean [ADDRESS_879501] deviation 2. Note that the 95% interval of this distribution 
allows for a more than 50-fold increase / decrease in odds depending on the covariate 
value
Data from 117 evaluable patients of the [INCB [ZIP_CODE] -251] study  (see Appendix 13 for the 
data) were added into the model in order to estimate log(α h), log(β h) and γ h. The posterior 
distributions when the data were added into the model can b e found in Table 9 -2.
Table 9-2 Posterior estimates for BLRM based on study  [INCB [ZIP_CODE] -251]
Posterior distribution of l og(α h), log(β h), data of study  [INCB [ZIP_CODE] -251], c* = 5.[ADDRESS_879502] deviations Correlation
log(αh), log(β h) -1.474, -0.324 0.260, 0.822 -0.383
γh -0.383 0.396 N/A
Step [ADDRESS_879503] the DLT probability  with accompan ying 95% 
credible intervals for the doses to be tested in the study  (total dail y dose = 10mg, 15mg, 20mg, 
25mg and 30mg) for a value of baseline platelet count = 87. This value corresponds 
approximately  to the expected mean baseline platelet count in stratum 1. A multivariate 
normal distribution for parameters (log(α), log(β)) was derived based on the predicted 
quantiles such that this distribution fits the predicted dose-response relationship for a baseline 
platelet count of 87. The predicted quantiles are given in Table 9-3.
The assumption about between -trial heterogeneity was captured in the prior distributions of 
the standard d eviation of (log(α),log(β)), denoted by  τ1and τ2. Both τ 1and τ2were assumed to 
follow a log-normal distribution with mean log(0.5) and standard deviation 0.01, assuming 
substantial between -trial heterogeneity . The resulting distribution can be found in Table 9-3.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879504]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879505]

[COMPANY_001] / Incyte Corp. Confidential Page 97
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Table 9-3 Predicted probability  of DLT quantiles for stratum 1 and distribution of 
log(alpha ), log( beta) after accounting for between trial heterogeneity
Predicted quantiles for doses to be tested in study  for c pred= log(87)
dose (total, daily ) 2.5thquantile Median 97.5thquantile
10mg 0.022 0.122 0.371
15mg 0.045 0.165 0.403
20mg 0.069 0.203 0.431
25mg 0.093 0.237 0.463
30mg 0.114 0.268 0.494
Distribution for log(α), log(β) accounting for between-trial heterogeneity  with τ1, τ2~ lognormal(0.5,0.012)
Parameter Means Standard deviations Correlation
log(α), log(β) -1.010, -0.259 0.876, 0.918 -0.103
Step 3
In order for the model to allow for the case that the predicted distribution assumes too high 
toxicity  in stratum 1, the prior distribution was set up as a mixture distribution. This mixture 
consists of the predicted prior distribution and a low-toxicity distribution which assumes the 
same dose-response relationship for stratum 1 as was seen in study  [INCB [ZIP_CODE]-251]
regardless of baseline platelet count, but accounting for between -trial heterogeneity . The exact 
procedure to derive the low -toxicity  distribution was a follows:
A non-informative prior for (log(α), log(β)) was derived in the same manner as for the 
main p rior as listed in Step 1 above.
Data from 117 evaluable patients of the [INCB [ZIP_CODE] -251] study  (see Appendix 13 for the 
data) were added into the model in order to estimate log(α), log(β). The posterior 
distributions when the data were added into the model can be found in Table 9 -4.
The assumption about heterogeneit y was captured in the prior distributions of the standard 
deviation of (log(α), log(β)), denoted b y τ1and τ 2. Both τ 1and τ 2were assumed to follow a 
log-normal distribution with mean log(0.75) and standard deviation 0.01, assuming 
substantial to large between -trial heterogeneity . The resulting distribution can be found in 
Table 9
-4.
Table 9-4 Distributions of model parameters and final prior distribution
Posterior distribution of log(α), log(β) using data from study  [INCB [ZIP_CODE] -251] .
Parameter Means Standard deviations Correlation
log(α), log(β) -1.443, -0.395 0.258, 0.942 -0.401
Distribution for log(α), log(β) accounting for between-trial heterogeneity  with τ 1, τ2~ lognormal(0.75,0.012)
Parameter Means Standard deviations Correlation
log(α), log(β) -1.447, -0.385 1.095, 1.412 -0.065
Step 4
A prior for the covariate (stratum indicator) parameter, γ, was developed by [CONTACT_655195] [ADDRESS_879506] a higher probability  of 
experiencing a DLT at a given dose level than patients from the population define d by [CONTACT_64264] 
1. Since there are no data available for this estimation, a conservative estimate was developed 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879507]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879508]

[COMPANY_001] / Incyte Corp. Confidential Page 98
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
based on clinical judgment that set the stratum [ADDRESS_879509] deviation 
equal to 0.354. This final prior is also gi ven in Table 9 -1.
Dose recommendation
After each cohort of patients is completed within a stratum, the posterior distribution for the 
model parameters will be obtained by [CONTACT_167889]. The posterior distributions of the model 
parameters are used to derive the posterior distributions for (d). The posterior distributions for 
(d)will be summarized by  [CONTACT_655196]
[0,16%) under -dosing
[16%,33%) targeted toxicity
[33%,100%] excessive toxicity
Following the principle of dose-escalation with overdose control (EWOC) 
(Babb et al 2008)
and (Neuenschwander et al 2008), after each cohor t of patients the recommended dose is the 
one with the highest posterior probability  of DLT in the target interval [16%, 33%) among the 
doses fulfilling 
the overdose criteria, namel y that there is less than 25% chance that the true 
rate of DLT falls in the excessive toxicity  interval. Note that the dose that maximizes targeted 
toxicity  is the best estimate of the MSSD, but it may not be a safe dose according to the 
overdose criteria if the amount of data is insufficient. Ideall y, if enough data are availabl e, the 
dose recommended for the next cohort and the best estimate of the MSSD will coincide.
The dose recommended by [CONTACT_655197] a clinical assessment of the toxicity  profiles observed thus 
far in determining the next dose to be investigated.
The first [ADDRESS_879510] data sufficient for determination of their inclusion or 
exclusion from the DDS, their data will be reviewed, together with all previously  reviewed 
data, for dose selection for patients in the next cohort. As an exception, the model will be re-
evaluated before enrollment of any additional patients to the cohort if 2 patients in the cohort 
experience DLT before the enrollment of the 3rdpatient.
9.4.3 Handling of missing values/censoring/discontinuations
During the dose-finding part of the trial, one additional patient may  be enrolled in each cohort 
for each patient who does not meet the criteria necessary  for inclusion in the dose -determining 
set. During the dose expansion part of the trial, one additional patient may be enrolled for 
each patient who does not meet the criteria necessary  for inclusion in the safet y set.At the 
time of the study  report , patients will have continuing events (e.g., adverse events) 
summarized using the data cut-off date as the date of completion, with an indication within 
the listings that the event is continuing.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879511]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879512]

[COMPANY_001] / Incyte Corp. Confidential Page 100
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Specific safet y event categories (SEC) will be considered. Such categories consist of one or 
more well-defined safet y events which are similar in nature and for which there is a specific 
clinical interest in connection with the study  treatment(s). SECs will be further defined in the 
study  Report and Analysis Plan (RAP). For each specified SEC, number and percentage of 
patients with at least one event part of the SEC will be reported.
DLTs will be listed and their incidence summarized by [CONTACT_64205], worst 
grade, t ype, and dose le vel. The DDS will be used for these summaries.
[IP_ADDRESS] Laboratory  abnormalities
For laboratory  tests covered by [CONTACT_15059] 
(CTCAE) version 4.03 ( NCI 2009),the study ’s biostatistical and reporting team will grade 
laboratory  data accordingl y. For laboratory  tests covered by [CONTACT_3989], agrade 0 will be 
assigned for all non- missing values not graded as 1 or higher. Grade 5 will not be used.
For laboratory  tests where grades are not defined by [CONTACT_3989], results will be graded by [CONTACT_15060]/normal/high classifications based on laboratory  normal ranges.
The following by-treatment summaries will be generated 
separatel y for hematology  and 
biochemistry  laboratory tests:
frequency  table for newly  occurring on -treatment grades 3 or 4 (see below for details)
shift tables using CTCAE grades to compare baseline to the worst on -treatment value
for laboratory  tests where CTCAE grades are not defined, shift tables using the 
low/n ormal/high/(low and high) classification to compare baseline to the worst on -
treatment value.
listing of all laboratory  data with values flagged to show the corresponding CTCAE 
grades and the classifications relative to the laboratory  normal ranges.
Time t o onset of grade 3 or higher SECs will be summarized by  [CONTACT_15994].
[IP_ADDRESS] Other safety  data
ECG
shift table baseline to worst on- treatment result for overall assessments
listing of ECG evaluations for all patients with at least one abnormality .
Vital signs
Defin itions of notably  abnormal results will be part of the RAP.
shift table baseline to worst on-treatment result
table with descriptive statistics at baseline, one or several post -baseline time points and 
change from baseline to this/these post -baseline time points.
Data from other tests (e.g., electrocardiogram or vital signs) will be listed, notable values 
flagged, and an y other information collected will be listed as appropriate.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879513]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879514]

[COMPANY_001] / Incyte Corp. Confidential Page 101
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
[IP_ADDRESS] Tolerability
Not applicable.
9.5.3 Resource utilization
Not applicable.
9.5.5 Pharmacokinetics, pharmacody namics and pharmacokinetics -
pharmacody namic s
[IP_ADDRESS] Pharmacokinetic data analy sis
The pharmacokinetics of INC424 in this patient population will be estimated by [CONTACT_655198] . INC424 plasma concentrations will be analyzed using NONMEM 
software. The data from this study  may be combined with data from other clinical studies to 
improve parameter estimation.
[IP_ADDRESS] Pharmacody namic data analy sis
Attempts will be made to characterize the dose/exposure -response relationship read outs of 
pharmacology , safet y and efficacy  collected during the study . Relationships between these 
exposures measures and spleen size, plasma cytokines, platelets, and presence of any dose 
limiting toxicity  will be initially  summarized graphicall y by [CONTACT_655199], e.g. 
Study  Day 15, Study  Day 29, and Study  Day 57. If there is evidence of a useful exposure -
response relationship, then it will be quantified by [CONTACT_655200], e.g., 
logistic regression.
[IP_ADDRESS] Pharmacokinetic -pharmacody namic data analy sis
The relationship between pharmacokinetic model predicted concentrations/parameters and 
pharmacologic, safety  and efficacy  read outs are planned. A longitudinal analysis of platelets 
(absolute values or change from predose) using predicted pharmacokinetics and baseline 
platelet value as covariates will be performed to assess platelet change over time.
INC424 plasma concentrations will be analy zed using population PK using NONMEM. PK 
data may be combined with data from other clinical studies to improve PK parameter 
estimation. The population PK model will be used to derive estimates of individual stead y-
state exposure measures using the initial planned dose regimen for the patients in study 
INC424A2201 (e.g., total mg dose on Day  1, C min, Cmax, and C avgcomputed over 24 hours).
A longitudinal population PK/PD 
analy sis of platelets will be performed to assess platelets 
incorporating dose interruptions and dose changes over time if thrombocytopenia is the DLT 
of most concern and alternative dose regimens or dose adjustment strategies need to be 
considered for potential use in new clinical studies.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879515]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879516]

[COMPANY_001] / Incyte Corp. Confidential Page 104
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
appropriate per the CTT. Approximately 21 patients are planned within each stratum in the 
dose-finding portion of the study assuming 3 patients treated at each dose level and 5 dose 
levels tested
. Once the MSSD is determined, an additional 10 patients will be enrolled per 
stratum in the safet y expansion phase in order to further evaluate the endpoints on patients 
starting at the MSSD. Based on a review of the interim analysis data, a decision was made to 
expand the 10 mg BID starting dose for Stratum 1.  Following the approval of Amendment 4, 
new patients enrolled to Stratum 1’s safety  expansion phase will begin treatment with 
ruxolitinib at 10 mg BID. In line with the original sample size specific ation for the MSSD 
cohorts (i.e. >9 patients for dose escalation phase and 10 patients for safety  expansion phase), 
approximately  20 patients in total will be enr olled, including those already  enrolled at the 10 
mg BID dose level in Stratum 1. 
Patients alread y taking the 15 mg BID dose in Stratum 1’s safet y expansion phase will 
continue to take their assigned dose.  Stratum 2 will maintain its original enrollment 
requirement of 10 patients at the MSSD.
Thus, as of Amendment 4, the approximate number of patients planned to be enrolled in the 
Dose -Determinin g Set (DDS) for this study  is 72 .
10 Ethical considerations and administrative procedures
10.1 Regulatory  and ethical c ompliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Code of Federal Regulations 
Title 21), and with the ethical principles laid down in the Declaration of Helsinki.
10.2 Responsibilities of the Investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. A signed and dated statement that the 
protocol and informed consent have been approved by [CONTACT_1201]/IEC/REB must be given to 
Sponsors before study  initiation. Prior to study  start, the Investigator is required to sign a 
protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with 
these documents and all of the instructions and procedures found in this protoc ol and to give 
access to all relevant data and records to Sponsors monitors, auditors, Sponsors Clinical 
Quality  Assurance representatives, designated agents of Sponsors , IRBs/IECs/REBs and 
regulatory  authorities as required.
10.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required by [CONTACT_6617]), IRB/IEC/REB -approved informed consent or, if incapable of 
doing so, after such consent has been provided by [CONTACT_655201]. In cases where the patient’s representative gives consent, the patient should be 
informed about the study  to the extent possible given his/her understanding. If the patient is 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879517]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879518]

[COMPANY_001] / Incyte Corp. Confidential Page 105
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
capable of doing so, he/she should indicate assent b y personall y signing and dating the written 
informed consent document or a separate assent form. Informed consent must be obtained 
before conducting any study -specific procedures (i.e. all of the procedures described in the 
protocol). The process of obtain ing informed consent should be documented in the patient 
source documents.
Sponsors will provide Investigator s in a separate document with a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by [CONTACT_655202]/IEC/REB, and a copy of the 
approved version must be provided to the Sponsors monitor after IRB/IEC/REB app roval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contr aception requirement for the 
duration of the study . If there is any question that the patient will not reliably compl y, they 
should not be entered in the study .
10.4 Discontinuation of the study
Sponsors reserve the right to discontinue this study  under the conditions specified in the 
clinical study  agreement. Specific conditions for terminating the study  are outlined in 
Section 3.9.
10.5 Publication of study  proto col and results
Sponsors assure that the key design elements of this protocol will be posted in a publicly 
accessible database such as clinicaltrials
.gov. In addition, upon study  completion and 
finalization of the study  report the results of this study  will be either submitted for publication 
and/or posted in a publicly  accessible database of clinical study  results.
10.[ADDRESS_879519] is acceptable provided it is legible and is a 
verified cop y of the original document.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879520]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879521]

[COMPANY_001] / Incyte Corp. Confidential Page 106
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
All eCRF data entered by [CONTACT_779] (including audit trail), as well as computer hardware and 
software (for accessing the data), will be maintained or made available at the site in 
compliance with applicable record retention regulation s. The Sponsors will retain the original 
eCRF data and audit trail.
10.[ADDRESS_879522] ensure anon ymity of the patients; patients must not be identified by 
[CONTACT_655203]. Signed informed consent forms and patient 
enrollment log must be kept strictly  confidential to enable pa tient identification at the site.
10.8 Audits and inspections
Source data/documents must be available to inspections by [CONTACT_655204].
10.[ADDRESS_879523] 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_655205]/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
11.[ADDRESS_879524] be approved by [CONTACT_655206], Health Authorities where required, and the IRB/IEC/REB . 
Only  amendments that are required for patient safety  may be implemented prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the Investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such cases, Sponsors should be notified of this action and the IRB/IEC/REB at 
the study  site should be informed within 10 working day s.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879525]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879526]

[COMPANY_001] / Incyte Corp. Confidential Page 107
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
12 References (avai lable upon request)
Babb J, Rogatko A, Zacks S (1998). Cancer phase I clinical trials: efficient dose escalation 
with overdose control. Stat Med.; 17 (10):1103- 20.
Barosi G, Mesa RA, Thiele J, et al; I nternational Working Group for M yelofibrosis Research 
and Treatment (I WG-MRT) (2008). Proposed criteria for the diagnosis of post -polycythemia 
vera and post -essential thrombocy themia m yelofibrosis: a consensus statement from the 
International Working Group for M yelofibrosis Research and Treatment. Leukemia; 
22(2):437-38.
Cervantes F, Dupriez B, Pereira A, et al (2009). A new prognostic scoring system for 
primary myelofibrosis based on a study  of the International Working Group for M yelofibrosis 
Research and Treatment. Blood ; 113:2895
-2901.
Deeg HJ, Gooley  TA, Fl owers ME, et al (2003). Allogeneic hematopoietic stem cell 
transplantation for myelofibrosis. Blood; 102:3912 -8.
Elliott M, Verstovsek S, Dingli D, et al (2007). Monocy tosis is an adverse prognostic factor 
for survival in younger patients with primary myelofibrosis. L euk Res. 31(11): 1503-9.
Ferenci P, Lockwood A, Mullen K, et al (2002). Hepatic encephalopathy --definition, 
nomenclature, diagnosis, and quantification: final report of the working party at the 11th 
World Congresses of Gastroenterology , Vie nna, 1998. Hepatology ; 35(3):716 –21.
Incyte Corporation (2009). Investigator’s Brochure INC424 Phosphate Capsules/Tablets, 
Version 8, September.
Mesa RA, Niblack J, Wadleigh M, et al (2007). The Burden of Fatigue and Quality  of Life in 
Myeloproliferative D isorders (MPDs). Cancer; 109:68 -
76.
National Cancer Institute (NCI) Common Terminology  Criteria for Adverse Events v4.0 
(CTCAE) online at the NCI  website, http://ctep.cancer.gov/reporting/ctc.html.
Neuenschwander B, Branson M, Gsponer T (2008). Critical aspects of the Bay esian approach 
to phase I cancer trials. Stat Med.; 27 (13):2420 -39.
Oken MM, Creech RH, Tormey  DC, et al (1982). Toxicity  and response criteria of the Eastern 
Cooperative Oncology  Group. 
Am J Clin Oncol.; 5(6):649-55.
Quintas -Cardama A, Vaddi K, L iu P, et al ( 2010). Preclinical characterization of the selective 
JAK1/JAK2 inhibitor I NCB018424: implications for the treatment of m yeloproliferative 
neoplasms. Blood; Epub ahead of print.
Slichter SJ (2004). Relationship between platelet count and bleeding risk in thrombocy topenic 
patients. Transfusion Medicine Reviews; 18;153-167.
Tefferi A, Vardiman JW (2008). Classification and diagnosis of m yeloproliferative 
neoplasms: The 2008 World Health Organization criteria and point -of-care diagnostic 
algorithms. L eukemia; 22:14-22.
Trussell J (2004). Contraceptive failure in the [LOCATION_002]. Contraception.;70:89 –96.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879527]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879528]

[COMPANY_001] / Incyte Corp. Confidential Page 108
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Verstovsek S, Kantarjian H, Mesa RA, et al (2010). Safet y and efficacy of INCB018424, a 
JAK1 and JAK2 inhibitor, in myelofibrosis. N Eng l J Med.; 16;363(12):1117-27.
World Medical Association Declaration of Helsinki Ethical Principles for Medical Research 
Involving Human Subjects. Adopted by  [CONTACT_941] 18th WMA General Assembl y, Helsinki, Finland, 
June 1964, and amended by  [CONTACT_941] 29th WMA General As sembly , Tok yo, Japan, October 1975, 
35th WMA General Assembly , Venice, Ital y, October 1983, 41st WMA General Assembl y, 
Hong Kong, September 1989, 48th WMA General Assembly , Somerset West, Republic of 
South Africa, October 1996, and the 52nd WMA General Assembl y, Edinburgh, Scotland, 
October 2000. Note of Clarification on Paragraph 29 added b y the WMA General Assembly, 
Washington 2002. Note of Clarification on Paragraph 30 added by  [CONTACT_118574] , Tok yo 2004. Available at <http://www.wma.net/e/policy /b3.htm>.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879529]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879530]

[COMPANY_001] / Incyte Corp. Confidential Page 109
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
[ADDRESS_879531] of A ppendices
Classification and diagnosis of my eloproliferative neoplasms and p roposed criteria for the 
diagnosis of post -polycythemia vera and post- essential thrombocy themia my elofibrosis
Information Regarding Effectiveness of Contraceptive Methods
Drugs that interfere with coagulation or inhibit platelet function
Hepatic encephalopath y grading according to West Haven Criteria
MDRD -eGFR Formula
CYP3A4 I nhibitors and Inducers
[LOCATION_001] Heart A ssociation (NYHA) Functional Classification
Eastern Cooperative Oncology  Group (ECOG) Performance Status
Clinical L aboratory  Tests
Prior calibration, h ypothetical dose escalation scenarios, and operating characteristics of 
the Bay esian logistic regression model
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879532]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879533]

[COMPANY_001] / Incyte Corp. Confidential Page 110
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix [ADDRESS_879534] -essentia l 
throm bocy themia myelofibrosis
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879535]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879536]

[COMPANY_001] / Incyte Corp. Confidential Page 111
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix 1a
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World 
Health Organization Criteria and point -of-care diagnostic algorithms (Tefferi 
and Vardiman, 2008)
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879537]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879538]

[COMPANY_001] / Incyte Corp. Confidential Page 112
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879539]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879540]

[COMPANY_001] / Incyte Corp. Confidential Page 113
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879541]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879542]

[COMPANY_001] / Incyte Corp. Confidential Page 114
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879543]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879544]

[COMPANY_001] / Incyte Corp. Confidential Page 115
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879545]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879546]

[COMPANY_001] / Incyte Corp. Confidential Page 116
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879547]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879548]

[COMPANY_001] / Incyte Corp. Confidential Page 117
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879549]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879550]

[COMPANY_001] / Incyte Corp. Confidential Page 118
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879551]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879552]

[COMPANY_001] / Incyte Corp. Confidential Page 119
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879553]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879554]

[COMPANY_001] / Incyte Corp. Confidential Page 120
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879555]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879556]

[COMPANY_001] / Incyte Corp. Confidential Page 121
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix 1b
Proposed criteria for the diagnosis of post -polycythemia vera and post-
essential thrombocy themia my elofibrosis: a consensus statement from the 
International Working Group for My elofibrosis Research and Treatment
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879557]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879558]

[COMPANY_001] / Incyte Corp. Confidential Page 122
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879559]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879560]

[COMPANY_001] / Incyte Corp. Confidential Page 124
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix 3
Information regarding effectiveness of contraceptive methods
Females of childbearing potential will be requested to use the combination of two highl y 
effective contraception methods.
For female patients participating in the s tudy:
Women of child -bearing potential, defined as all women physiolog ically  capable of becoming 
pregnant, unless they are using highl y effective methods of contraception throughout the 
study  duration inclusive of 30 day safety follow up. Highl y effective contraception methods 
include: 
* Total abstinence (when this is in line with the preferred and usual lifesty le of the subject). 
Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and 
withdrawal are not acceptable methods of contraception 
* Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) or tubal ligation at least six weeks before taking study  treatment. In case of 
oophorectom y alone, only when the reproductive status of the woman has been confirmed by 
[CONTACT_104] 
* Male sterilization (at least 6 months prior to screening). For female subjects on the study  the 
vasectomized male partner should be the sole partner for that subject. 
* Combination of any  two of the following (a+b or a+c, or b+c): 
a.Use of oral, injected or implanted hormonal methods of contraception or other forms of 
hormonal contraception that have comparable efficacy  (failure rate <1%), for example 
hormone vaginal ring or transdermal hormone contraception. 
b.Placement of a n intrauterine device (IUD) or intrauterine s ystem (IUS) 
c.Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault 
caps) with spermicidal foam/gel/film/cream/vaginal suppository . 
In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_879561] had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age 
appropriate, history  of vasomotor symptoms) or have had surgical bilateral oophorectomy 
(with or without hysterectomy ) or tubal ligation at least six weeks ago. In the case of 
oophorectom y alone, only when the reproductive status of the woman has been confirmed by 
[CONTACT_6592]. 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879562]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879563]

[COMPANY_001] / Incyte Corp. Confidential Page 125
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix [ADDRESS_879564] 
thrombin 
inhibitorsNSAIDs and 
AcetaminophenFood supplements
Aspi[INVESTIGATOR_248]
(more than 125 
mg/day )Heparin Aminocaproic 
AcidFondaparinux Urokinase Argatroban Ibuprofen, Naproxen, 
Fenoprofen, Ketoprofen, 
Flurbiprofen, Oxaprozin, 
Indomethacin, Sulindac, 
Etodolac, Ketorolac, 
Diclofenac, Nabumetone, 
Pi[INVESTIGATOR_18234], Meloxicam, 
Tenoxicam, Droxicam, 
Lornoxicam, Isoxicam, 
Mefenamic acid, 
Meclofenamic acid, 
Flufenamic acid, 
Tolfenamic acidNattokinase (extracted 
and from a Japanese 
food called natto)
Ticlopi[INVESTIGATOR_655140] (present 
in the earthworm 
Lumbricus bimastus )Prasugrel Phenprocoumon Tissue 
plasminogen 
activators ( t-Pa):
Alteplase
Reteplase
TenecteplaseDabigatran
Cilostazol Acenocoumarol
Abciximab Anisindione
Eptifibatide Dalteparin
Tirofiban Danaparoid
Dipyridamole Enoxaparin
Epoprostenol Tinzaparin
Phenindione
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879565]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879566]

[COMPANY_001] / Incyte Corp. Confidential Page 126
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix [ADDRESS_879567] Haven Criteria
Grade Symptoms
1 Trivial lack of awareness; Euphoria or anxiety; Shortened attention span; Impaired 
performance of addition or subtraction
2 Lethargy or apathy; Minimal disorientation for time or place; Subtle personality 
change; Inappropriate behavior
3 Somnolence to semi -stupor, but responsive to verbal stimuli; Confusion; Gross 
disorientation
4 Coma (unresponsive to verbal or noxious stimuli)
(Ferenci et al 2002 )
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879568]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879569]

[COMPANY_001] / Incyte Corp. Confidential Page 127
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix [ADDRESS_879570] -eGFR Formula
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879571]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879572]

[COMPANY_001] / Incyte Corp. Confidential Page 128
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix 7
CYP3A 4 inhibitors and in ducers
Medications that can induce CYP3A4
Strong inducers Moderate inducers Weak inducers Unclassified inducers
avasimibe bosentan amprenavir topi[INVESTIGATOR_655141] (R -modafinil)
phenytoin modafinil dexamethasone
rifabutin nafcillin echinacea
rifampin ritonavir garlic
St. John's wort talviraline gingko
tipranavir glycyrrhizin
methylprednisolone
nevirapi[INVESTIGATOR_655142]:
Inducer classification:
Strong inducers may  result in a substrate AUC decreased by ≥ 80%.
Moderate inducers may  result in a substrate AUC decreased by 50- 80%.
Weak inducers may  result in a substrate AUC decreased by 20 -50%.
This list is compi[INVESTIGATOR_655143] t he FDA’s “Guidance for Industr y, Drug Interaction Studies”, the Indiana 
University School of Medicine’s Drug Interactions Database, and the University of W ashington’s Drug 
Interaction Database. This list may  not be comprehensive and may be updated periodic ally. Refer to 
[COMPANY_001] Oncology Clinical Pharmacology Internal Memorandum, Drug -drug interactions (DDI) 
Database (last updated [ADDRESS_879573] 2010) for update or more details.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879574]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879575]

[COMPANY_001] / Incyte Corp. Confidential Page 129
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Medications that can inhibit CYP3A4
Strong inhibitors Moderate inhibitors Weak inhibitors
clarithrom ycin amprenavir alprazolam
conivaptan aprepi[INVESTIGATOR_655144]070
indinavir atazanavir amlodipi[INVESTIGATOR_655145] M100240
verapamil nilotinib
oral contraceptives (e.g. drospi[INVESTIGATOR_187306], 
norgestimate, and ethinyl estradiol)
peppermint oil
propi[INVESTIGATOR_655146]:
Inhibitor classification:
Strong inhibitors may  result in a substrate AUC > 5 -fold increase.
Moderate inhibitors may  result in a substrate AUC ≥ 2-fold increase and < 5 -fold increase.
Weak inhibitors may result in a substrate AUC ≥ 1.25 -fold increase and < [ADDRESS_879576] is compi[INVESTIGATOR_655147]’s “Guidance for Industry , Drug Interaction Studies”, 
the Indiana Universit y School of Medicine’s Drug Interactions Database, and the Universit y 
of Washington’s Drug Interaction Database. This list may not be comprehensive and may be 
updated periodicall y. Refer to [COMPANY_001] Oncology  Clinical Pharmacology  Internal 
Memorandum, Drug -drug interactions (DDI) Database (last updated [ADDRESS_879577] 2010) for 
update or more details.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879578]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879579]

[COMPANY_001] / Incyte Corp. Confidential Page 130
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix 8
[LOCATION_001] Heart A ssociation (NYHA ) Functional Classification
NYHA  
ClassSymptoms
I No sy mptoms and no limitation in ordinar y physical activity. E.g., shortness of 
breath when walking, stair climbing, etc.
II Mild sy mptoms (mild shortness of breath and/or angina pain) and slight limitation 
during ordinar y activit y.
III Marked limitation in activity due to sy mptoms, even during less -than- ordinary 
activity (e.g. walking short distances, ~ >20 -100m). Comfortable only at rest.
IV Severe limitations. Experiences sy mptoms even while at rest, mostly bed bound 
patients
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879580]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879581]

[COMPANY_001] / Incyte Corp. Confidential Page 132
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879582]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879583]

[COMPANY_001] / Incyte Corp. Confidential Page 133
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879584]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879585]

[COMPANY_001] / Incyte Corp. Confidential Page 134
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879586]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879587]

[COMPANY_001] / Incyte Corp. Confidential Page 135
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix 11
Eastern Cooperative Oncology  Group (ECOG) Performance Status
Grade Performance Status
0 Fully active, able to carr y on all pre-disease performance without restriction
1 Restricted in phy sically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature, eg, light house work, office work
2 Ambulatory and capable of all self care but unable to carry out any work activities. Up 
and about more than 50% of waking hours
3 Capable of only limited self care, confined to bed or chair more than 50% of waking 
hours
4 Completely disabled. Cannot carry  on any self care. Totally confined to bed or chair
5 Dead
Source: ( Oken et al1982 )
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879588]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879589]

[COMPANY_001] / Incyte Corp. Confidential Page 136
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix 12
Clinical Laboratory  Tests
Serum Chemistry Hematology Coagulation
ALT Complete Blood Count (CBC) INR
AST
Alkaline phosphatase Differential including reporting 
of % blastsPTT
Total bilirubin D-dimer or FDP
Direct bilirubin
Albumin Platelets Fibrinogen
Lactate dehydrogenase
Creatinine
BUN
Sodium
Potassium
Glucose
Calcium
Uric acid
Other
Pregnancy Test:
Female patients of childbearing 
potential only; serum test at 
Screening and Follow -up. Urine 
test at subsequent visits per the 
Description of Study Visits 
(Section 6)
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879590]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879591]

[COMPANY_001] / Incyte Corp. Confidential Page 137
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Appendix 13
Prior calibration, hy pothetical dose escalation scenarios, and operating 
characteristics of the Bay esian logistic regression model
Statistical models and dose recommendation
An adaptive Bayesian logistic regression model (BLRM) guided by [CONTACT_540894] (EWOC) principle will guide the dose-escalation to determine the maximal 
safe starting dose (MSSD) of INC424. The model will use accumulated data on observ ed 
DLTs at each dose level and stratum. Bayesian inference will be used to assess the risks of 
overdose at each dose level. The use of Bay esian response adaptive models for Phase I studies 
has been advocated by [CONTACT_3558]  (EMA) guideline on small 
populations (2006) and by (Rogatko et al 2007 )and is one of the key elements of the Food 
and Drug Administration’s (FDA) Critical Path Initiative. For this trial a 3-parameter 
Bayesian logist ic regression model will be used in order to establish the safety  of oral INC424 
treatment in patients with myelofibrosis and platelet counts between 50 
x109/L and 100 
x109/L.
INC424 is currentl y being evaluated in two randomized, pi[INVESTIGATOR_36491], [INCB18424-351]
and [INCB
[ZIP_CODE]-352] , in patients with myelofibrosis and baseline platelet counts > 100 
x109/L. In these trials, the starting dose of INC424 is platelet dependent: patients with platelet 
counts between 100 x109/L and 
200 x109/L begin at 15 mg b.i.d. , and patients with platelet 
counts > 200 x109/L begin at 20 mg b.i.d.
The doses used in the above mentioned pi[INVESTIGATOR_655148] a Phase I/II, dose-finding study , [INCB18424-251] . In [INCB18424 -251] , a total 
of 154 patients at a total of 8 different starting doses were explored, both in b.i.d. and q.d. 
schedules. Table Aprovides a summary  of the number of patients treated at each of the 4 
startin g b.i.d. dose levels (n = 117), and Table Bprovides the patient -level data used to derive 
this summary . In addition, the total number of patients with a “DLT” (as defined in this 
current protocol [CINC424A2201] ) was retrospectively  determined. It is this retrospectivel y 
applied DLT definition that is summarized in Table A and Table B .
Table A Incidence of DLTs by [CONTACT_655207] I/II study  
[INCB18424 -251] for patients who started on a b.i.d. regimen, 
where DLT is defined as in the current protocol
Dose schedule Total daily dose (mg) No of 
patientsNo (%) of patients with DLTs
b.i.d. 20 mg
30 mg
50 mg
100 mg30
35
47
54 / 30 (13.3)
4 / 35 (11.4)
17 / 47 (36.2)
1 / 5 (20.0)
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879592]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879593]

[COMPANY_001] / Incyte Corp. Confidential Page 138
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Table B DLT data from all patients starting at a b.i.d. dose schedule in 
Study [INCB18424 -251]. Data provided are baseline platelet count 
(x109/L) and an in dicator variable for observation of a DLT per the 
current study criteria (1 = y es, 0 = no)
Total daily dose
20 mgTotal daily dose
30 mgTotal daily dose
50 mgTotal daily dose
100 mg
476,0 226,0 998,1 319,0
174,0 318,1 647,0 611,0
372,0 667,0 360,0 151,0
268,0 283,1 298,0 102,1
113,0 639,0 454,0 394,0
125,1 245,0 170,1
761,0 605,0 214,1
231,0 208,0 426,0
115,0 468,0 163,0
574,0 240,0 285,0
162,0 593,0 116,1
483,0 478,0 277,0
119,0 637,0 805,1
130,0 624,0 871,0
156,1 211,0 810,0
117,0 285,0 832,0
103,0 425,0 170,1
424,0 622,0 210,1
208,0 288,0 148,0
596,0 209,0 118,0
444,1 454,0 286,0
336,0 237,0 138,0
425,0 317,0 1195,1
218,0 304,0 193,0
133,0 231,0 223,0
223,0 602,0 483,0
123,0 544,0 214,0
153,0 247,0 184,0
195,0 449,0 147,1
147,1 683,0 118,1
379,0 245,1
468,1 415,1
316,0 138,0
351,0 315,1
220,1 372,0
372,0
202,0
168,0
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879594]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879595]

[COMPANY_001] / Incyte Corp. Confidential Page 139
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Total daily dose
[ADDRESS_879596] 28 days of treatment, the prior 
distribution will be updated with the accumulated DLT data. Posterior probabilities for the 
rate of DLT by  [CONTACT_655208]. Selection of the next dose will be 
based on these probabilities as well as on other safety  and laboratory  data.
See Section 9.4.2 of the protocol for BLRM and for an elaborate explanation of the derivation 
of the prior.
Hypothet ical dose escalation scenarios
In order to show how the Bayesian model reacts, different hypothetical scenarios were 
investigated. The designs should make reasonable decisions during a study  based on the 
observed toxicities particularly  in early cohorts. Table Cshows on-study decisions made for 
each of 4 different specified hypothetical DLT observations based on the BLRM. Note that 
per the protocol design, stratum 2 does not begin enrollment until dose level 3 (total daily 
dose = 20 mg) has been declared open in stratum 1.
Table C Hypothetical dose escalation scenario (S1 = Stratum 1, S2 = 
Stratum 2)
Scenario Cohort Total Daily  Dose 
ReceivedNumber of DLTs / 
Number of patientsRecommended Total Daily  
Dose (mg) for Next Cohort
1 1 (S1)
2 (S1)
3 (S1), 1 (S2)10 mg (S1)
15 mg (S1)
20 mg (S1), 10 mg (S2)0 / 3 (S1)
≤ 1 / 3 (S1)
≤ 1 / 3 (S1), 0 / 3 (S2)15 mg (S1)
20 mg (S1), 10 mg (S2)
25 mg (S1), 15 mg (S2)
2 (all S1) 1
2
310 mg
10 mg
10 mg1 / 3
1 / 3
≥ 1 / 310 mg
10 mg
STOP
3 (all S1) 1 10 mg ≥ 2 / 3 STOP
4 (all S1) 1
2
3
410 mg
15 mg
10 mg
15 mg0 / 3
2 / 3
0 / 3
1 / 315 mg
10 mg
15 mg
15 mg
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879597]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879598]

[COMPANY_001] / Incyte Corp. Confidential Page 140
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Simulated operating characteristics
In the previous Section, some individual hypothetical scenarios were investigated to 
understand how the BLRM reacts within a clinical trial. In this Section, the performance of 
the BLRM over many trials is investigated via simulation. This approach allows for an 
understanding of how the BLRM behaves on average based on an assumed “truth”, i.e., 
assuming the true underlying relationship between dose and probabilit y of DLT were known.
Hypothetical true relationships between dose and probability  of DLT
A total of 4 different true relationships between dose and probability  of DLT [P(DL T)] were 
assumed. For each scenario, the relationship between dose and P(DLT) is specified for each 
stratum.
Figure A display s the assumed P(DLT) for INC424 doses for the four scenarios. For sce narios 
[ADDRESS_879599] is assumed.
Figure A Dose -DLT relationship of the different scenarios (solid line = 
stratum 1, dashed line = stratum 2)
10 15 20 25 300.0 0.4 0 8P(DLT)Scenario 1
10 15 20 25 300.0 0.4 0 8Scenari o 2
10 15 20 25 300.0 0.4 0.8
NC424 T otal Daily  Dose (mg)P(DLT)Scenario 3
10 15 20 25 300.0 0.4 0.8
NC424 T otal D aily Dose (mg)Scenari o 4
Simulation parameters
A total of 1000 trial simulations were used for each scenario and the total minimum number 
of DLTs to control the declaration of MSSD was fixed to one. No more than 1 dose level was 
allowed to be increased in single step.
The number of patients to enroll in each cohort and stoppi[INVESTIGATOR_655149]:
Cohort size: 3
Approximate number of patients enrolled: 31
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879600]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879601]

[COMPANY_001] / Incyte Corp. Confidential Page 141
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Minimum number of patients treated at the recommended MSSD: 9
Metrics
Operating characteristics were reviewed for the simulations to compare the relative 
performance under each true scenario. The metrics reviewed were:
Probability  of recommending a target dose as the MSSD (correct final decision) (I)
Probability  of recommending a dose with true P(DL T) ≥ 33.3% as the MSSD (patient risk) 
(II)
Probability  of recommending a dose with true P(DL T) < 16% as the M SSD (III)
MSSD < smallest positive dose (i.e. 10mg) (IV)
Average proportion of patients receiving a target dose on study  (V)
Average proportion of patients receiving a dose with true P(DLT) ≥ 33.3% on study  (VI)
Average proportion of patients receiving a d ose with true P(DLT) < 16% on study  (VII)
Average number of patients per study  (VIII)
Results
The simulated operating characteristics presented below show that the model performs well 
under the wide range of hy pothetical scenarios investigated.
Table D and Table E summarize the results from the simulations performed for both strata.
Table D Summary  metrics of simulations for Stratum 1
Scenario I II
III IV V VI VII VIII
1 .537 .306 .146 .011 .327 .308 .365 21
2 .362 .074 .418 .146 .309 .146 .545 18
3 .961 0 .012 .027 .723 0 .276 21
4 .963 0 .018 .019 .711 0 .289 21
Table E Summary  metrics of simulations for Stratum 2
Scenario I II III IV V VI VII VIII
1 .358 .064 .475 .103 .306 .126 .568 18
2 .143 .125 0 .732 .575 .426 0 9
3 .841 0 .073 .086 .655 0 .345 20
4 .674 .136 .047 .143 .589 .176 .235 18
Figure Bshows the proportions of patients receiving INC424 falling into the different toxicity  
intervals for the four hy pothetical scenarios. In this figure, the proportion of patients treated in 
the targeted toxicity  interval is 33%, 31%, 72% and 71% for scenari os 1, 2, 3 and 4, 
respectivel y, in stratum 1, and 31%, 58%, 66%, and 59%, respectively , in stratum 2. The 
proportion of patients treated in the over-dosing interval is higher than 25% in 2 situations. In 
Scenario 1, stratum 1, 31% of patients are treated in the over-dosing interval. This is due to 
the relativel y low P(DLT) that is possible in this interval (40%). In Scenario 2, stratum 2, 43% 
of patients are treated in the over-dosing interval. However, this is due to the simulation 
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879602]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879603]

[COMPANY_001] / Incyte Corp. Confidential Page 142
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
assumption that all doses in the study  are in the overdosing interval. This assumption is 
extreme since it assumes a greater than [ADDRESS_879604] of the simulations (72%) for this scenario in this 
stratum resulted in [correctly ] declaring an MSSD that was below the range under study .
Figure B Proportions of patients receiving targeted dose, who are under -
dosed or who are over -dosed
Underdosin g Target Dosing OverdosingStratum 1
Stratum 20.0 0.4 0.8Scenario 1
Underdosin g Target D osing OverdosingStratum 1
Stratum 20.0 0.4 0.8Scenari o 2
Underdosin g Target Dosing OverdosingStratum 1
Stratum 20.0 0.4 0 8Scenario 3
Underdosin g Target D osing OverdosingStratum 1
Stratum 20.0 0.4 0 8Scenari o 4
The MSSD dose selections under the four hypothetical scenarios are presented in Figure C. 
The MSSD dose selection in the over-dosing interval occurs in less than 25% in all but 1 of 
the strata in one ofthe scenarios (Scenario 1, stratum 1), where it is 30.6%. This is due to the 
underl ying DLT probability  rate in the lowest dose in the over-dosing interval, where the 
P(DL T) is 40%.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879605]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879606]

[COMPANY_001] / Incyte Corp. Confidential Page 143
Amended Protocol Version 04 –Clean Protocol No. CINC424A2201
Figure C MSSD dose selection under different dose -toxicity  scenarios
Underdosin g Target Dosing OverdosingStratum 1
Stratum 20.0 0.4 0.8Scenario 1
Underdosin g Target D osing OverdosingStratum 1
Stratum 20.0 0.4 0.8Scenari o 2
Underdosin g Target Dosing OverdosingStratum 1
Stratum 20.0 0.4 0 8Scenario 3
Underdosin g Target D osing OverdosingStratum 1
Stratum 20.0 0.4 0 8Scenari o 4
References (available upon request)
Babb J, Rogatko A, Zacks S (1998). Cancer phase I clinical trials: efficient dose escalation 
with overdose control. Stat Med; 17: 1103 -1120.
Neuenschwander B, Branson M, Gsponer T (2008). Critical aspects of the Bay esian approach 
to phase I cancer trials. Statistics in Medicine; 27: 2420 -
2439.
Neuenschwander B, Capkun -Niggli G, Branson M, et al (2010). Summarizing Historical 
Information on Controls in Clinical Trials. Clin Trials; 7(1): 5-18.
This document (  in docbase CREDI_EH) has been digitally signed with external signatures using Entrust PKI.
Signatures manifested as of 7/31/2015 6:08:42 PM, signing status at this time:  Completed (3 of 3 signatures) 
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 13:56:[ADDRESS_879607]
Approved for report publication by  [CONTACT_655150], 31 Jul 2015 02:08:30 PM EDT
Approved for report publication by  [CONTACT_655150], Jul 31, 2015 10:00:[ADDRESS_879608]
